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ABSTRACT

Staphylococcus aureus is a pathogenic bacterium that inflicts a large amount of human
suffering using an arsenal of virulence factors to cause minor to life-threatening infections.
Both the accessory gene regulator (agr) operon, a virulence regulatory pathway that
controls expression of over 200 virulence factors, and alpha-hemolysin (Hla), a key poreforming toxin, play a significant role in infection severity. Given the clinical trial failures
of S. aureus vaccine candidates and the prevalence of antibiotic-resistant strains, novel and
effective treatment options are urgently needed. Chapter 2 describes a novel virus-like
particle (VLP) -based vaccine inducing agr-I-inhibiting antibodies and reducing infection
severity in vivo. Chapter 3 describes two novel VLP-based vaccines inducing Hlaneutralizing antibodies targeting a linear neutralizing domain, reducing Hla-mediated
pathogenesis during in vivo toxin challenge. These vaccines significantly add to the tool
belt of effective S. aureus virulence inhibitors and may help address the antimicrobial
resistance crisis.
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CHAPTER 1: Introduction and Background

Clinical Relevance of Staphylococcus aureus

i.

Introduction to S. aureus

The important pathogen Staphylococcus aureus (S. aureus, or colloquially referred to as
“Staph aureus”) is a cocci-shaped bacterium most often found in the nares or skin of
humans and animals. It is a Gram-positive bacterium and facultatively anaerobic. S. aureus
was first differentiated from S. albus, now called S. epidermidis, in 1884 by the German
microbiologist Friedrich Julius Rosenbach. S. aureus was named for its physical features
observable by microscope, which grows in “golden” (aureus) “grape-like cluster”
(staphylococcus) colonies. S. aureus is a member of the Bacterial family
Staphylococcaceae and the Staphylococcus genus, which are distinguished from
enterococci and streptococci by its production of catalase, which converts hydrogen
peroxide to water and oxygen. S. aureus is often hemolytic when grown on blood agar1 and
is differentiated from other staphylococci because it tests positive in the expression of
coagulase2.
S. aureus is capable of being both a human commensal and invasive pathogen. The
bacterium asymptomatically colonizes approximately 20% of the human population
persistently, and up to 60% intermittently3. The most common S. aureus colonization sites
include, but are not limited to, the anterior nares and respiratory tract, gastrointestinal (GI)
tract, and skin45. S. aureus non-persistent carriers will often become recolonized with their
prior S. aureus strain6. Much effort has been put into investigating factors important for
1

colonization by the bacteria, but not as much is known about host factors that determine
colonization status7. S. aureus combines the strategies of enhanced host-binding and
immune evasion to facilitate its colonization. Adhesion is mediated by the expression of
microbial surface components recognizing adhesive matrix molecules (MSCRAMMs),
which directly interact with molecules on host epithelium or extracellular matrix. Specific
examples include the fibrinogen-binding clumping factors (ClfA and ClfB)8–10 and
fibronectin-binding proteins (FnBPA and FnBPB)11,12. Immune evasion is achieved
through the sequestration of antibody by surface protein A (SpA), which prevents
opsonization by binding the Fc region of IgG13, and through the inhibition of complementmediated phagocytosis14–16. Of great clinical concern is that the interaction between cell
wall anchored proteins on adjacent S. aureus cells contributes to biofilm formation.
Biofilms are microbial communities in which bacterial aggregates adhere to a biomaterial
surface and are encased in a matrix of protein and extracellular DNA17. As the use of
inserted prosthetic devices and medical implants has risen, so too has the incidence of
infection risk. Device-associated infections are one-fourth of all health-care associated
infections in the Untied States18, and staphylococci account for about 80% of these
infections19,20. S. aureus in biofilms have greater resistance to antibiotics than non-biofilm
S. aureus and are therefore more difficult to treat19.
S. aureus can cause many types of life-threatening infections including
endocarditis, osteomyelitis, pneumonia, bacteremia, metastatic infections, sepsis, and toxic
shock syndrome21. Mortality rates for S. aureus bacteremia are estimated at between 10%
and 30%22. By breaches in the skin, such as ulcers or surgical or traumatic wounds, and
other mechanisms not yet identified, S. aureus colonization can turn into invasive
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infection23. Skin and soft tissue infection (SSTI) comprises the majority of S. aureus
infections, estimated at greater than 90% of all S. aureus infections24. SSTI range in
severity from superficial infections to necrotizing fasciitis25. S. aureus is typically present
in lesions of atopic dermatitis patients26 and causes chronic inflammatory reactions through
the release of toxins and various other effector proteins26. The expression of hundreds of
virulence factors, which broadly includes toxins, adhesion molecules, enzymes, and
immune evasion factors, drives S. aureus pathogenicity and severity of infection.
The Centers for Disease Control and Prevention (CDC) attributes 11,285 annual
deaths to methicillin-resistant S. aureus (MRSA) alone27. Importantly, this estimate does
not include deaths due to methicillin sensitive S. aureus (MSSA). A 2013 study estimated
the economic burden on U.S. society from community-acquired MRSA infection was
between $1.4 billion to $13.8 billion, depending on incidences and definitions of
community-acquired MRSA. Hospitalization rates and mortality were the largest cost
drivers in this study28. A 2007 report found that MRSA killed more Americans than
HIV/AIDS, Parkinson’s disease, emphysema, and homicide combined27,29. MRSA
infections are prevalent, composing approximately 50% of all S. aureus strains isolated
from S. aureus infection30,31, and their resistance to antibiotics renders MRSA infections
to be more difficult to treat. MRSA strains are categorized as either hospital-acquired
MRSA, HA-MRSA, or community-acquired MRSA, CA-MRSA. CA-MRSA strains are
typically believed to be more virulent than HA-MRSA strains because of their ability to
infect otherwise healthy individuals.
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ii.

Risk Factors for Infection

Populations at increased risk of S. aureus infection include individuals colonized with S.
aureus, diabetics, hemodialysis patients, HIV/AIDS patients, individuals with leukocyte
dysfunction, and IV drug users6,21,23,32–34. Populations at risk for S. aureus infection who
otherwise appear healthy include prisoners, athletes, military personnel, healthcare
workers, elderly, and children. There are also defined populations with genetic
susceptibilities to S. aureus infection. Included are individuals carrying a STAT3 mutation,
or Job’s Syndrome, which is characterized by a defect in IL-17 production35–37. Another
genetic predisposition to increased risk of S. aureus infection are individuals with a
mutation in the NOX2 gene, resulting in chronic granulomatous disease (CGD), which
causes NADPH oxidase dysfunction and failure of neutrophils to produce reactive oxygen
species (ROS)38,39. Included among genetic susceptibilities are also Chediak-Higashi
syndrome, which affects lysosomal trafficking40, TLR2 deficiencies41, and complement
deficiency42, which all have increased risk of S. aureus infection43. Identifying mutations
that render the host more susceptible to S. aureus infection can highlight the important role
of host immune responses in normal clearance of the pathogen. Neutrophils are recruited
by Th17 cells (which mature from IL-17 signaling) and are highly important in clearance
of S. aureus during infection44–46. In the absence of Th17-mediated neutrophil recruitment
or during impaired clearance due to defective ROS production, S. aureus infection can
remain persistent, demonstrating the important roles played by each of these features of the
immune system. Of great importance is the finding that X-linked agammaglobulinemia
(XLA) patients, who are not able to generate mature B cell, do not have increased
susceptibility to S. aureus infection, suggesting normal antibody response to infection is
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not important in host defense nor sufficient to protect against S. aureus. The non-essential
role B cell immunity plays in normal S. aureus infection has been demonstrated
experimentally in B cell- and antibody-deficient mouse models47–49.

iii.

S. aureus Antibiotic Resistance

Antibiotics have contributed to the increase in American lifespan from 56.4 years in 1920
to 80 years now50. The global spread of microbial antibiotic resistance is one of the greatest
crises facing humans today. Misuse and overuse of antibiotics has fueled the emergence of
multiantibiotic-resistant pathogens51–53. Included amongst these is MRSA. Methicillin
resistance was first detected in S. aureus in 1961, less than two years after introduction54,55.
Both MRSA and MSSA are resistant to most penicillin-like β-lactam antibiotics due to the
production of β-lactamase, but MRSA has additional resistance to staphylococcal βlactams provided by a mutation in a β-lactam antibiotic target, penicillin binding protein 2
(PBP2), which has decreased β-lactam affinity56. The mecA gene encodes the mutated
protein, PBP2a, and is acquired through horizontal gene transfer57. Mobile genetic
elements (MGEs) allow for the exchange of genetic material between bacteria via
horizontal gene transfer and play an important part in S. aureus acquiring antibiotic
resistance. Exchanged genetic material can include transposons, bacteriophages, plasmids,
pathogenicity islands, and in the case for mecA, staphylococcal cassette chromosomes58.
Vancomycin was introduced into practice in 1972 to combat methicillin resistance
in S. aureus and in coagulase-negative staphylocci52,56. S. aureus strains exhibiting
resistance to vancomycin, known as vancomycin-resistant S. aureus (VRSA), and strains
with intermediate resistance, known as vancomycin-intermediate S. aureus (VISA), were
5

first reported in the U.S. in the early 2000s and 1990, respectively59. Although reported
VRSA cases have been rare52, the spread of strains resistant to a common antibiotic
prescribed for treating MRSA such as vancomycin creates some cause for concern. Fewer
antibiotics with novel mechanisms of action have been introduced in the last decades60,
which bodes poorly in the fight against antibiotic-resistant pathogens.

S. aureus Virulence Factors and Regulation

i.

Introduction to S. aureus virulence

S. aureus expresses an arsenal of factors that contribute to pathogenesis61. Fine-tuned
expression of virulence factors is controlled by multiple virulence regulation mechanisms
that operate both independently and in concert with each other. The virulence regulation
pathways that perhaps are most significant to causing disease are the agr (accessory gene
regulator) operon, the SaeRS system, and SarA62–64, which are described below. Regulated
by each of these pathways is the key cytotoxin alpha-hemolysin (Hla), also described here.

ii.

Accessory Gene Regulator (agr) Operon

The agr operon controls much of S. aureus virulence65. Quorum sensing (QS) systems such
as the S. aureus agr pathway utilize signals received by the external environment to provide
a readout of the local concentration of bacteria cells, resulting in a coordinated
transcriptional change. The S. aureus agr pathway is shown in Figure 1.1 A. Encoded in
the agr locus are the RNAII and RNAIII transcripts66, under control by the P2 and P3
promoters, respectively. RNAII encodes the four agrBDCA genes that conduct QS
6

signaling. The AgrD propeptide associates at the cell membrane with AgrB67. Through a
process not yet fully understood, AgrD is cleaved at the C-terminus and cyclized by a
thiolactone bond between the cysteine side chain and the terminal carboxylate68. The
thiolactone bond results in the formation of a five-membered C-terminal macrocycle ring
(Figure 1.1 B), which provides the nascently cleaved peptide increased stability and
resistance to proteolysis69. AgrB mediates the translocation of the peptide to the cell
surface, where a final N-terminal cleavage event occurs65. As a result of this process, AgrD
is transformed into the cyclic, 7-9 residue, “autoinducing peptide”, or “AIP”. Once AIP
reaches an external concentration ranging from 10-30nM70, the peptide serves as a ligand
to the transmembrane receptor histidine kinase molecule, AgrC. Upon AIP binding, AgrC
undergoes autophosphorylation and is activated71. Importantly, AIP must be in its cyclic
conformation in order to activate its cognate AgrC receptor and otherwise does not activate
AgrC when linearized70. Activation of AgrC initiates a classical two-component signaling
event, where active AgrC signals to the AgrA response regulator by transferring its
phosphorylation group71. Activated AgrA directly binds and activates the P2 promoter,
serving as a positive feedback loop by increasing the expression of the agr proteins. The
activation of AgrA also induces transcription of the P3 promoter, resulting in RNAIII
production72. Phosphorylated AgrA also directly regulates the expression of phenol soluble
modulins (PSMs)73, virulence factors that play a role in inducing chemotaxis, promoting
inflammation, and causing cellular lysis. RNAIII is the primary effector of active agr, and
it functions by post-transcriptionally promoting or inhibiting the translation of numerous
S. aureus RNA transcripts. RNAIII directly or indirectly regulates over 100 different
virulence factors65. The indirect upregulation of a multitude of these factors is through
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RNAIII’s inhibition of the “repressor of toxins” (Rot), a SarA-like regulatory protein which
itself negatively regulates many secreted virulence factors74.

8

Figure 1.1 - S. aureus agr and AIPs. (A) Schematic of the accessory gene regulator (agr)
pathway and its contribution to virulence. The propeptide AgrD is cleaved and cyclized
when exiting through the AgrB pore, creating the autoinducing peptide (AIP). AIP binds
and activates AgrC, which phosphorylates AgrA. Active AgrA increases phenol soluble
modulin (PSM) expression, causes positive feedback through activation of the P2 promoter
(encoding agrBDCA), and increases RNAIII transcription, which increases overall
production of secreted virulence factors and decreases virulence factors responsible for
adhesion. (B) S. aureus AIP sequences. Sequence and structure of AIP1, AIP2, AIP3, and
AIP4 (encoded by agr-I, -II, -III, and –IV, respectively). A five-membered macrocycle is
formed at the C-terminus by thiolactone linkage between the cysteine side chain and the
terminal carboxylate. Cys residues necessary for this linkage are highlighted in yellow.
Adapted from Daly et al.75
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As S. aureus divides, agr signaling increases, with peak activity shown using a
fluorescent agr-I reporter strain during in vivo infection of SKH-1 mice at approximately
3 and 72 hours76. In general, agr activation downregulates the expression of cell wall
anchored adhesion factors and conversely increases the expression of secreted virulence
factors. Increased secreted factors regulated by agr include pore-forming toxins (such as
Hla, delta-hemolysin, and the bicomponent leukotoxins), proteases, lipases, superantigens,
and PSMs. Downregulated factors linked to agr activation include SpA, FnBP, and
MSCRAMMS, which promote colonization65. Upregulated secreted virulence factors
contribute to disease by promoting inflammation, tissue invasion, immune cell lysis, and
immune evasion. For a comprehensive list of agr-regulated virulence factors and their
contribution to promoting disease, see the thorough review by Thoendel et al.65
S. aureus agr-deficient strains are less invasive and less able to cause pathogenicity
associated with invasive infection than wildtype strains77. For this reason, agr QS
inhibition has been actively studied for its potential in reducing S. aureus pathogenesis75,78–
81

. Four S. aureus agr alleles exist: agr-I, agr-II, agr-III, and agr-IV68,82, with each allele

encoding a unique AIP sequence. Of great importance, isolates of each allele can cause
disease in humans83; therefore, any effective S. aureus treatment targeting agr must be
capable of targeting all four alleles. Table 1.1 describes numerous approaches inhibiting
agr signaling to reduce pathogenicity in animal models. There are no human trials yet using
an agr inhibitor. Among these treatments are small-molecule inhibitors to disrupt AgrA
activity75,80,84, inhibitory AIP from other Staphylococcal species85,86, a monoclonal
antibody (mAb) against AIP479, and the first agr active vaccine against agr-IV81. However,
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prior to the work in this dissertation an active vaccine against agr-I, -II, or -III had not been
reported.
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Table 1.1 – Preclinical Treatments Targeting S. aureus agr in Animal Models
Treatment

MOA

Model

AgrC
noncompetitive
inhibitors

Ms nasal
colonization,
arthritis

Reduced colonization.
Reduced pathology.

Murray et al.87

Unknown

Ms SSTI

Reduced dermonecrosis.

Muhs et al.88

AIP4 mAb (AP424H11)
Ambuic acid

AIP4
neutralization
AgrB inhibitor

Ms SSTI, i.p.
challenge
Ms SSTI

Reduced dermonecrosis.
Increased survival.
Reduced abscess
formation.

Park et al.79

Apicidin

AgrA inhibitor

Ms SSTI

F12, F19

AgrA inhibitors

Lysionotin

Unknown

Ms
bacteremia
Ms PNA

OHM

AgrA inhibitor

Ms SSTI

Resveratrol

Unknown

Ms PNA

Reduced pathology.
Promoted clearance.
Increased survival.
Promoted clearance.
Reduced pathology.
Promoted clearance.
Reduced dermonecrosis.
Promoted clearance.
Reduced pathology.

RIP

RNAII/III
inhibition
AgrC
antagonist
AgrC
antagonist
AgrA inhibitor

Ms PNA

Reduced pathology.

Ms i.d.
infection
Ms SSTI

Reduced dermonecrosis.
Promoted clearance.
Reduced dermonecrosis.

Ms skin
colonization,
i.d. infection
Ms SSTI

Reduced dermonecrosis.
Promoted clearance.

Sully et al.80

Reduced inflammation.

Ms i.p.
infection, BSI

Increased survival.

Baldry et al.96;
Nielsen et al.97
Yeo et al.98

Ms SSTI

Reduced dermonecrosis.

Small Molecules
3-oxo-C12-HSL,
tetramic acid,
tetronic acid
analogues
430D-F5

S. caprae AIP
S. simulans AIP
Savirin

Solonamide B
STZ, FU

Active Vaccines
Mimotope vaccine

AgrC
antagonist
Unknown

AIP4
neutralization

Results

Reference

Todd et al.89 ;
Nakayama et
al.90
Parlet et al.84
Greenberg et
al.91
Teng et al.92
Daly et al.75
Tang et al.93
Zhou et al.94;
Gov et al.95
Paharik et al.85
Brown et al.86

O'Rourke et
al.81

Abbreviations: agr – accessory gene regulator; AIP – autoinducing peptide; BSI – bloodstream
infection; FU – floxuridine; i.d. – intradermal; i.p. – intraperitoneal; mAb – monoclonal antibody; MOA
– mechanism of action; Ms – mouse; OHM – ω-hydroxyemodin or omega-hydroxyemodin; PNA –
pneumonia; RIP – RNAIII-inhibiting peptide; S. caprae – Staphylococcus caprae; S. simulans –
Staphylococcus simulans; SSTI – skin and soft tissue infection; STZ - Streptozotocin
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iii.

SaeRS TCS and SarA

The sae (S. aureus exoprotein expression) locus is defined as a regulator of exoprotein
production, and encodes four genes: saeP, saeQ, saeR, and saeS99,100. Similar to agr, Sae
activity operates through a histidine kinase receptor, SaeS, and a response regulator,
SaeR101, making it a two-component system (TCS). SaePQ forms an inhibitory complex
with SaeS, which leads to phosphorylation and decreased signal transduction to SaeR64.
SaeS activates SaeR, which then binds the promoter region of target genes and induces the
expression of 20 virulence factors including coagulase, nuclease, adhesins, exfoliative
toxin, toxic shock syndrome toxin-1 (TSST-1), and various exotoxins including Hla99,101–
103

. The SaeRS TCS is regulated by environmental cues and host signals, where low pH

(5.5) and high salt concentration (1M NaCl) result in the transcriptional inhibition of the
sae locus63,104. SaeRS has been found to play a role in dictating infection severity62,77,105
and neutrophil defense106 during infection, and it regulates virulence factors entirely
independently from agr.
SarA is a member of the SarA protein family of S. aureus and is expressed by three
different promoters. SarA is negatively regulated by the SarA-like protein SarR and by the
alternative sigma factor σB (SigB), which itself responds to stresses and helps S. aureus
adapt to different environments64. SarA regulates virulence by activating agr and
repressing three SarA-like regulatory proteins: Rot, SarH1, and SarT64,107,108. SarA also
regulates different virulence factor targets post-transcriptionally by binding and altering
the turnover of mRNA109.
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iv.

Alpha-Hemolysin (Hla)

Alpha-toxin, also called alpha-hemolysin (or Hla), is one of the more heavily studied
virulence factors of the S. aureus-secreted toxins. Hla is encoded in the S. aureus
chromosome and expressed by most S. aureus strains110. Soluble Hla monomers bind to
host cells by a surface-displayed cellular receptor and metalloprotease, ADAM10111, and
oligomerize into a heptameric pore structure in the host membrane112. The Hla pore allows
for escape of Ca2+, K+, and ATP110, and can result in cellular lysis. In addition to lysing
erythrocytes, Hla damages or kills many different cellular targets, including monocytes,
neutrophils, T cells, keratinocytes, endothelial cells, and platelets113. Furthermore, Hla can
disrupt epithelial cell junctions at sub-lytic concentrations through the activation of
ADAM10, resulting in cleavage of E-cadherin114. Hla can also modulate the immune
response by activating the inflammasome, leading to proinflammatory cytokine IL-1β
production115, which will cause further damage to the host during infection.
Hla plays an important role in dictating infection severity and participates in many
types of infection. S. aureus isolates that cannot produce Hla have decreased pathogenesis
when used in animal models116, demonstrating the toxin’s important role in infection.
Infection with Hla-mutant strains have been shown to have decreased severity compared
to wildtype in several models, including SSTI117, pneumonia118, and sepsis114, to name a
few. Hla expression correlates with severity, as highly-virulent USA300 strains have
increased expression of Hla compared to most other strains77,119. Individuals with
antibodies against Hla have been shown to more often have positive outcome during S.
aureus sepsis120, and a study in children showed individuals with a high anti-Hla titer may
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have been less likely to have recurring S. aureus infection121. Overall, this demonstrates
the importance of inducing an anti-Hla humoral response to limit S. aureus pathogenicity.
Considering the high colonization rate in humans for S. aureus, it is of no surprise
most have circulating antibodies against this pathogen122. However, natural exposure does
not induce protective immunity, as recurring infections are generally common123. Several
Hla vaccines and mAb approaches have been developed and tested in preclinical animal
studies with great success, as shown in Table 1.2. Many experimental vaccines developed
against Hla have exploited a single residue mutation in the Hla N-terminus (H35L) that
renders the toxin unable to form a pore. The inactive Hla H35 toxoid has been paired with
adjuvants and other immunogenic components to be used for vaccination117,124–127. Other
active vaccines include the 50 N-terminal amino acids fused to a glutathione S-transferase
(GST) tag (GST-HlaH35L 1-50), and a detoxified Hla lacking the membrane spanning stem,
called “HlaPSGS”127,128. The passive transfer of antibodies induced to HlaH35L and GSTHla35L have also shown success in animal models128–130. Suvratoxumab, also known as
MEDI4893 or LC10, is a mAb developed by MedImmune that has shown success in both
animal models and in phase I clinical trials131–139.
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Table 1.2 - Preclinical Animal Studies Targeting Hla by Active or Passive
Immunization
Methoda

Active/Passive

Model

Results

Reference

Active/Passive

Reduced pathology. Reduced
bacterial burden.
Reduced bacterial burden
(surg.). No change in bacterial
burden (SSTI). Reduced
dermonecrosis (both).
Reduced pathology. Reduced
bacterial burden.

Adhikari et
al.140
Adhikari et
al.141

AT62 (Hla1-62)

Active/Passive

Full-length
HlaH35L toxoid

Active

Ms PNA,
bacteremia
Ms surgical
wound
infection,
SSTI
Ms PNA

Full-Length
HlaH35L/H48L, PVL
toxoids
GST-HlaH35L
(1-50)
Hla mAb
α-HlaH35L
HlaPSGS

Active

Ms PNA

Reduced bacterial burden.
Increased survival.

Active/Passive

Ms SSTI

Reduced dermonecrosis.

Passive

Ms PNA

Active

MAP-Hla LND
(114-141)
MAP-Hla Nterminus (1-19)

Passive

Ms i.n.
infection
Ms SSTI

Reduced pathology. Reduced
bacterial burden.
Increased survival.

Passive

Ms SSTI

Reduced dermonecrosis.
Reduced bacterial burden.
Reduced dermonecrosis.

Passive

Ms SSTI

Reduced dermonecrosis.

Passive

Ms PNA

Passive

Ms PNA

Passive

Rb ABSSSI

Passive

Rb PNA; Fr
PNA
Ms sepsis

Reduced pathology. Reduced
bacterial burden.
Reduced pathology. Reduced
bacterial burden.
Reduced dermonecrosis.
Reduced bacterial burden.
Reduced pathology. Reduced
bacterial burden (both).
Increased survival.

*Suvratoxumab

Passive
Passive

Ms IP coinfection
with C.
albicans
Ms SSTI,
PNA, sepsis
Ms SSTI

Increased survival.

Bubeck
Wardenburg et
al.124
Tran et al.142

Kennedy et
al.128
Ragle et al.130
Fiaschi et al.127
Oscherwitz et
al.143
Oscherwitz et
al.144
Tkaczyk et
al.131
Hua et al.132
Hua et al.133
Le et al.134
Diep et al.135
Surewaard et
al.136
Todd et al.137

Passive
Reduced pathology. Reduced
Tkaczyk et
Suvratoxumab,
bacterial burden (all).
al.138
ClfA mAb
Passive
Reduced pathology. Reduced
Hilliard et al.139
Suvratoxumab,
bacterial burden.
LZD/VAN
*Suvratoxumab is also referred to as MEDI4893 and LC10. aCommas indicate combined antigens.
Abbreviations: ABSSSI – acute bacterial skin and soft structure infection; C. albicans – Candida
albicans; ClfA – Clumping factor A; Fr – ferret; GST – glutathione S-transferase; Hla – alpha-hemolysin
i.n. – intranasal; LZD – linezolid; mAb – monoclonal antibody; MAP – multiple antigenic peptide; Ms –
mouse; PNA – pneumonia; Rb – rabbit; SSTI – skin and soft tissue infection; VAN - vancomycin
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Progress and Challenges of S. aureus Vaccines

i.

Early history of S. aureus vaccines

Despite much effort, no vaccine against S. aureus has passed Phase III clinical trials. Table
1.3 shows a comprehensive list of both failed vaccines and vaccines currently undergoing
testing and development, from preclinical to phase III trials. The first S. aureus vaccine to
enter Phase III was StaphVax, developed by Nabi Biopharmaceuticals145. The vaccine
included purified capsular polysaccharide 5 and 8 (CP5/CP8) conjugated with
pseudomonal exotoxin A and was intended to induce a humoral response to these surfacedisplayed targets to mediate opsonophagocytosis. The Phase III trial testing StaphVax was
interrupted due to the lack of protection above the levels of the placebo146. Another early
S. aureus vaccine that failed in Phase III was Merck’s V710, which included purified ironregulated surface determinant B (IsdB)147. Unexpectedly, subjects receiving V710 not only
failed to have enhanced protection, but showed increased mortality compared to
individuals receiving placebo, after which the trial was terminated147,148. These early
failures were the beginning of the struggle to develop an effective vaccine for human use.

ii.

Speculation for vaccine clinical failures

Difficulty in developing a successful vaccine is not a problem imposed by all bacteria.
Effective vaccines have been successfully developed against Streptococcus pneumoniae,
Haemophilus influenzae type b, and against the bacterial pertussis and tetanus toxins.
However, S. aureus poses a large number of unique clinical challenges to overcome for
vaccine development. A large challenge is that protective immunity is not completely
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defined as an opsonic or neutralizing antibody response. Whereas an opsonic response
against the S. pneumoniae capsule in the pneumococcal vaccine and a neutralizing antibody
(NAb) response against tetanus and pertussis toxins in the Tdap vaccine are clearly
protective149–151, there is much debate surrounding the best immune response to target S.
aureus. Yet it may be important that in the two early S. aureus vaccine failures, StaphVax
and V710, the induction of an opsonophagocytic antibody response was the sole
mechanism of protection. Furthermore, the expression of surface-displayed proteins such
as SpA and staphylococcal binder of immunoglobulin (Sbi), which bind antibodies by the
Fc region, plays a role in preventing antibody-mediated clearance of S. aureus13,152,153.
In addition to having an incomplete understanding of protective immunity, another
clinical challenge is that S. aureus utilizes an arsenal of virulence factors with overlapping
or redundant function, so neutralization of a single virulence factor may not be protective.
S. aureus also has many strains that have genetic variability, where different combinations
of virulence factors are present154. Furthermore, agr and other virulence regulatory
pathways provide S. aureus with a large amount of phenotypic variability, where single
virulence factors are expressed only during specific environmental conditions or phases of
growth21,64. These three challenges essentially allow S. aureus to be a “moving target” for
vaccination, and they justify the hypothesis of a multiple-component vaccine being more
efficacious.

iii.

Current progress for S. aureus vaccines

Although natural humoral immunity is not essential to protect against infection, there are
many examples when high serum antibody titers against specific virulence factors
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correlates with protection46,120,121,155, suggesting boosting specific titers can be protective.
Additionally, there is evidence that an effective Th17 response, promotes neutrophil
recruitment to defend against invading pathogens, may lower risk of infection, reinfection,
or limit pathogenesis46,156–158. Vaccines promoting the induction of neutralizing antibodies,
opsonizing antibodies, Th17 immunity, or a combination are currently under development
and in clinical trials. These vaccines are listed in Table 1.3, which was primarily formed
in reference to the review by Redi et al.159.
Many vaccines are currently under development that target both surface-displayed
proteins and secreted virulence factors, by induction of opsonizing and neutralizing
antibodies, respectively. Toxins commonly targeted for neutralization include Hla and
PVL. In combination with an opsonizing humoral response, some vaccines induce cellular
mediated immunity, such as the SA4Ag vaccine by Pfizer and NDV3 by NovaDigm
Therapeutics160–163. NDV3 is unique in that it utilizes an antigen from C. albicans, Als3p,
to induce a cross-reactive humoral and cell-mediated immune response against S. aureus
ClfA163. An important observation for current S. aureus vaccine studies is that the only
vaccines tested in phase III were abandoned, and the two most recent phase II studies were
stopped prematurely, granted one study stopped due to difficultly recruiting participants
(NDV3). The SA4Ag STRIVE study (see Table 1.3), which recruited subjects undergoing
elective spinal surgery and measured S. aureus BSI occurring after surgery, was stopped
in futility due to underwhelming vaccine efficacy results. Perhaps of importance as well is
that these failed or stopped clinical trial studies exclusively induced opsonizing antibodies
instead of neutralizing, suggesting vaccines inducing NAbs, perhaps in addition to an
opsonizing antibody or cellular response may prove more successful.
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Table 1.3 - S. aureus Vaccines in Preclinical and Clinical Phases
Vaccine

Preclinical
4C-Staph

Glycovaxine
IBT-V02

N.A.

N.A.

PentaStaph

SpA-DKKAAFnbpA37-507

Target(s)a

Developer

HlaH35L,
EsxAB,
FhuD2,
Csa1A (alum
adjuvanted)
CP5, CP8,
rHlaH35L
Hla, PVL,
SEA, SEB,
TSST-1
(toxoids)

Novartis
(now GSK)

Humoral
(O/N)

Protection in ms PNA
and arthritis.

Torre et
al., 2015;
165
Mancini
et al., 2016

GSK

Humoral
(O+N)
Humoral
(N)

Protection in ms PNA
and bacteremia.
Protection in ms PNA
and bacteremia.

126

rSdrE,
rIsdA,
rSdrD, rIsdB
(alum
adjuvanted)
rPBP2a

Novartis
(now GSK)

Humoral
(O)

Protection in ms
infection.

Pasture
Institute of
Iran and
IAUPS
Nabi and
USUHS
(now GSK)

Humoral
(O)

Protection in ms
bacteremia.

169

Humoral
(O/N)

Results unclear.

170

NSFC

Humoral
(O) and
cellular

Protection in ms PNA
and SSTI.

171

CP5, CP8,
HlaH35L,
LukS-PV,
WTA
SpA-FnBPA
(recombinant
fusion
protein)

IBT

Immune
Responseb

Result

Original
Reference

164

Wacker et
al., 2014
140
Adhikari
et al., 2012;
166
Karauzum
et al., 2013;
167
Aman et
al., 2018
168
StrangerJones et al.,
2006

Haghighat
2017

Schaffer
and Lee,
2009
Yang
2018

a

Hyphen designates conjugation to antigen. Comma designates multiple antigens. bHumoral responses
classified as “O” (opsonizing), “N” (neutralizing), or “O/N” (both).
Abbreviations: CP5, CP8 – Capsular polysaccharide 5, 8; Csa1A – conserved staphylococcal antigen 1
A; EsxAB – secretion system protein A, B; FhuD2 – ferric hydroxamate receptor 2; FnBPA –
fibronectin-binding protein A; GSK – GlaxoSmithKline; Hla – alpha-hemolysin; IAUPS – Islamic Azad
University, Pharmaceutical Sciences Branch; IBT – Integrated BioTherapeutics; IsdA, IsdB – ironregulated surface determinant A, B; LukS-PV – Panton-Valentine leucocidin component S; ms – mouse;
N – neutralizing; NSFC – National Natural Science Foundation of China; PBP2a – penicillin binding
protein 2a; O – opsonizing; PNA – pneumonia; PVL – Panton-Valentine leucocidin; SdrD, E – serineaspartate repeat protein D, E; SEA, SEB – staphylococcal enterotoxin A, B; SpA – surface protein A;
SSTI – skin and soft tissue infection; USUHS – Uniformed Services University of the Health Sciences;
WTA – wall teichoic acid
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Table 1.3 – Continued
Vaccine

Phase I
GSK2392103A

Target(s)a

Developer

Immune
Responseb

Result

Original
Reference

TTCP5/CP8,
rHla, rClfA
rSEB (alum
adjuvanted)

GSK

Humoral
(O/N)

Completed. No further
development.

172

IBT and
NIAID

Humoral
(N)

173

N.A.

rSEB, rC1,
rTSST-1

IBT

Humoral
(N)

N.A.

rHla,
rLukS-PV
rALS3p-N
(C. albicans
antigen,
alum
adjuvanted)
DTCP5/CP8,
rClfA,
rMntC

Nabi

Humoral
(N)
Humoral
(O) and
cellular

Completed. Safety,
demonstrated production
of NAbs.
Completed. Safety,
evaluating possible phase
II trial.
Completed. Safety,
robust immune response.
Completed safety and
immunogenicity.

Pfizer

Humoral
(O) and
cellular

160

Begier et
al., 2017;
162
Frenk et
al., 2017

Whole cell
vaccine

VRI

Humoral
(O) and
cellular

Completed. Safety,
robust immune response,
ongoing phase IIb in
adults receiving spinal
surgery.
Completed. Safety and
tolerability. No further
development.

rALS3p-N
(C. albicans
antigen,
alum
adjuvanted)
DT-CP5/8,
rClfA,
rMntC

NovaDigm
Therapeutics

Humoral
(O) and
cellular

Stopped. Enrollment
issues.

163

Pfizer

Humoral
(O) and
cellular

Stopped. No protection
vs placebo in elective
spinal fusion surgery
patients.

160

IBT-V01
(STEBvax)

NDV3

SA4Ag (PF06290510)

SA75

Phase II
NDV3

SA4Ag
STRIVE

NovaDigm
Therapeutics

Levy et
al., 2015
Chen et
al., 2016
174

Roetzer et
al., 2016
175

Landrum
et al., 2017
163
Schmidt
et al., 2012

Giersing et
al., 2016

Schmidt
et al., 2012

Begier et
al., 2017;
162
Frenk et
al., 2017

a

Hyphen designates conjugation to antigen. Comma designates multiple antigens. bHumoral responses
classified as “O” (opsonizing), “N” (neutralizing), or “O/N” (both).
Abbreviations: Als3p – agglutinin like sequence 3 protein; ClfA – Clumping factor A; CP5, CP8 –
Capsular polysaccharide 5, 8; DT – diphtheria toxin; GSK – GlaxoSmithKline; Hla – alphahemolysin; IBT – Integrated BioTherapeutics; LukS-PV – Panton-Valentine leucocidin component S;
MntC – manganese transporter protein C; ms – mouse; N – neutralizing; NIAID – National Institute
for Allergy and Infectious Disease; O – opsonizing; SEB – staphylococcal enterotoxin B; STRIVE –
STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy; TT – tetanus toxoid; VRI – Vaccine
Research Institute
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Table 1.3 – Continued

Vaccine

Target(s)a

Developer

Immune
Responseb

Result

Phase III
StaphVAX

CP5/CP8

Nabi

Humoral
(O)

Stopped. No protection
vs placebo in end-stage
renal patients.

V710

IsdB

Merck

Humoral
(O)

Stopped. Increased
mortality in vaccinated
subjects postcardiothoracic surgery.

Original
Reference

145

Fattom et
al., 2004;
146
Fattom et
al., 2015
147
Fowler et
al., 2013;
148
McNeely
et al., 2014

a

Hyphen designates conjugation to antigen. Comma designates multiple antigens. bHumoral responses
classified as “O” (opsonizing), “N” (neutralizing), or “O/N” (both).
Abbreviations: Als3p – agglutinin like sequence 3 protein; ClfA – Clumping factor A; CP5, CP8 –
Capsular polysaccharide 5, 8; DT – diphtheria toxin; MntC – manganese transporter protein C; ms –
mouse; O – opsonizing
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Virus-Like Particles as a Vaccine Platform

i.

Introduction to VLPs

Vaccines against S. aureus have not been successful thus far in human clinical trials,
therefore innovate approaches have been encouraged by the National Institute of Allergy
and Infectious Diseases (NIAID)176. One such innovative approach is the use of
bacteriophage virus-like particles (VLPs) as vaccine platforms. Bacteriophage virus-like
particles (VLPs) are composed of recombinant viral coat protein and therefore resemble
authentic virions177. The VLP coat protein gene can be expressed in E. coli via plasmid
transformation, and recombinant coat proteins self-assemble upon expression. They are
non-infectious and carry no inherent pathogenicity due to the lack of a viral genome.
Furthermore, VLP vaccines are FDA-approved (see Gardasil, Cervarix, and Gardasil9178),
demonstrating their safety. Therefore, if experiments using VLPs are successful in animal
models, they may potentially translate into human studies more readily.
VLPs serve as a highly flexible vaccine platform by the ability to display nearly
any heterologous epitope on the particle surface, by either conjugation or direct cloning.
Safe and effective VLP-based vaccines have been developed to be used against diverse
pathogens such as HPV and HCV, to ailments including Alzheimer’s Disease,
hypertension, certain cancers, and high cholesterol, to name a few179–183. Their small size,
typically between 20 and 100 nm184 , allows for quick filtration into lymph nodes, where a
rapid immune response against the VLP occurs. Multivalent display of surface epitopes
serves as a strong activator of B cells by inducing B cell receptor cross-linking, resulting
in a robust humoral response that is typically long-lasting and of a high titer185. The strength
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of VLP immunostimulation is demonstrated by their ability to break self-tolerance, as
demonstrated by Chackerian et al186.
Potential advantages of using epitope-based vaccines such as VLPs is that antibody
induction to an antigen can be primarily focused toward a neutralizing epitope. Using
epitope-focused vaccines can induce antibodies to “cryptic epitopes”, or epitopes that may
be neutralizing but are either non-immunogenic or fail to elicit antibodies during natural
infection187. Furthermore, broadly neutralizing antibodies can even have deleterious
effects, as in the case with vaccines against RSV and dengue virus providing antibodydependent enhancement of disease188,189, and such a negative effect may be mitigated by
focusing on a single epitope.

Hypotheses

Due to the high virulence of S. aureus, its many disease states, and its resistance to current
antibiotics, the development of novel treatment options are of critical need. Considering
the failures of all vaccine attempts used thus far, many of which are “conventional”
vaccines promoting opsonophagocytosis and utilizing either a full-length antigen or
subunit approach, innovative, rationally designed vaccines could prove to be the critical
answer to combat this crisis. Therefore, we hypothesize that vaccination with
bacteriophage VLP-based vaccines displaying epitopes important to a key virulence
regulatory pathway and key virulence factor will reduce S. aureus virulence-mediated
pathogenesis in the host. Chapter 2 and Chapter 3 will test this hypothesis investigating
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the host immune response to and protection elicited from VLP-based vaccines inducing
neutralizing antibodies targeting the agr operon and the key secreted toxin, Hla.
In Chapter 2, we explore the efficacy of utilizing a vaccine designed to induce a
neutralizing antibody response against secreted AIP, of the agr operon. We hypothesize
that vaccination with an AIP-VLP will (i) induce antibodies that bind AIP, that (ii) induced
AIP-binding antibodies inhibit agr-signaling, and (iii) vaccination will provide mice with
in vivo protection during S. aureus SSTI challenge (Figure 1.2 A).
In Chapter 3, we designed VLPs displaying a known linear neutralizing domain
(LND) from the key secreted cytotoxin, Hla. This epitope was identified by Oscherwitz et
al.143, who demonstrated that passive transfer of antibodies against this domain provided
in vivo protection in a S. aureus SSTI mouse challenge model. We hypothesize that
vaccination with Hla-LND-VLPs will (i) induce antibodies that bind and neutralize Hla,
(ii) protect target cells from Hla-mediated lysis, and (iii) will protect from Hla-mediated
pathogenesis during in vivo subcutaneous Hla challenge (Figure 1.2 B).
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Figure 1.2 – Model for inhibiting S. aureus agr and Hla via vaccination. (A) Antibody
induced from VLP-AIP vaccination sequesters AIP, inhibiting AgrC activation and
downstream activation of AgrA, resulting the in failure of the P2/P3 promoters to be
transcribed. This inhibitory effect limits agr gene transcription and inhibits the
transcription of RNAIII, ultimately decreasing agr-regulated secreted virulence factors
from being expressed. (B) (Top) Without intervention, Hla monomers form a pore in target
cell membrane and cause cellular lysis. Hla subcutaneous challenge results in damaged
skin and a strong inflammatory reaction. (Bottom) With VLP-Hla-LND vaccination,
induced antibodies sequester Hla by binding to LND region, preventing both target cell
lysis and Hla-mediated pathology during Hla challenge.
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Abstract
Staphylococcus aureus is the leading cause of skin and soft tissue infections (SSTIs) and
mounting antibiotic resistance requires innovative treatment strategies. S. aureus uses
secreted cyclic autoinducing peptides (AIPs) and the accessory gene regulator (agr) operon
to coordinate expression of virulence factors required for invasive infection. Of the four
agr alleles (agr types I-IV and corresponding AIPs1-4), agr type I isolates are most
frequently associated with invasive infection. Cyclization via a thiolactone bond is
essential for AIP function; therefore, recognition of the cyclic form of AIP1 may be
necessary for antibody-mediated neutralization. However, the small sizes of AIPs and
labile thiolactone bond have hindered vaccine development. To overcome this, we used a
virus-like particle (VLP) vaccine platform (PP7) for conformationally-restricted
presentation of a modified AIP1 amino acid sequence (AIP1S). Vaccination with PP7AIP1S elicited AIP1-specific antibodies and limited agr-activation in vivo. Importantly, in
a murine SSTI challenge model with a highly virulent agr type I S. aureus isolate, PP7AIP1S vaccination reduced pathogenesis and increased bacterial clearance compared to
controls, demonstrating vaccine efficacy. Given the contribution of MRSA agr type I
isolates to human disease, vaccine targeting of AIP1-regulated virulence could have a
major clinical impact in the fight against antibiotic resistance.

Introduction
Between 2000 and 2012, the incidence of skin and soft tissue infections (SSTI) in the USA
is estimated to have increased 40%, with treatment expenditures increasing from $4.4
billion to $13.8 billion in 2012 dollars28. Among emergency room patients, the majority of
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SSTIs are caused by Staphylococcus aureus, and over half of these isolates are methicillinresistant (MRSA)30,31. Compared to antibiotic-susceptible strains, MRSA SSTI treatment
failure requires added interventions with associated increases in human suffering and
medical costs190. Given the ongoing antibiotic resistance crisis, the recurrent nature of S.
aureus SSTI123, and the lack of an approved S. aureus vaccine to date191, there is an urgent
need for alternative approaches to combat infections caused by MRSA.
The production of virulence factors required for S. aureus SSTI is largely regulated
by the accessory gene regulator operon (agr)77,192 through a bacterial communication
system known as quorum sensing. Induction of agr signaling depends upon the
accumulation of small, secreted autoinducing peptides (AIPs) to activate a receptor
histidine kinase, AgrC, in the bacterial cell membrane65,193. AgrC activation drives
downstream production of the effector molecule, RNAIII, which in turn regulates
expression of over 200 virulence genes contributing to invasive infection192. S.
aureus isolates express one of four agr alleles (agr-I to agr-IV), with each secreting a
unique AIP (AIP1-AIP4) and expressing a corresponding AgrC. Previously, both an antiAIP4

monoclonal

antibody (mAb)79,194 and

an

AIP4

immunologic

mimotope

vaccine81 showed protection against infection caused by agr type IV isolates. However,
antibody or vaccine targeting of signaling by agr type I isolates, which are most associated
with invasive S. aureus infection83,195, has not been reported.
S. aureus AIP1 is an eight amino acid peptide (YSTCDFIM) cyclized by a
thiolactone bond between the Cys4 side-chain and the carboxyl group of the C-terminal
residue (Met8) (Figure 2.1 A). Given that cyclization is essential for function, immune
recognition of the cyclic form of AIP1 may be necessary for antibody-mediated
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neutralization. However, the small size of these peptides makes them innately nonimmunogenic and, together with the labile nature of the thiolactone, increases the difficulty
of vaccine development79,81,196. We sought to overcome these challenges using a
bacteriophage virus-like particle (VLP) vaccine platform. These VLPs self-assemble from
recombinantly expressed bacteriophage coat proteins which can be genetically altered for
surface presentation of practically any epitope in a multivalent format that virtually
guarantees strong immunogenicity resulting in high titer, high affinity, and long-lasting
antibodies177. Specifically, we hypothesized that a vaccine produced by conformationallyrestricted presentation of the AIP1 amino acid sequence on the surface of bacteriophage
VLPs would elicit antibodies against native AIP1 and induce immune control of agr type
I-regulated virulence.
To test this, we produced a VLP-based agr type I vaccine by cloning a modified
AIP1 amino acid sequence (YSTSDFIM) into an immuno-prominent surface loop (the ABloop) of the Pseudomonas aeruginosa RNA bacteriophage PP7 coat protein197–200. As
expected, the resulting vaccine (PP7-AIP1S) elicited antibodies, which recognized AIP1 in
vitro and was efficacious in a murine SSTI model upon challenge with a highly virulent
MRSA agr type I isolate. Compared to controls, PP7-AIP1S vaccination resulted in
reduced agr function and agr-regulated virulence factor production at the site of infection.
Importantly, PP7-AIP1S vaccination significantly reduced S. aureus pathogenesis, based
on dermonecrosis and weight loss, and increased bacterial clearance, findings consistent
with enhanced host innate defense in the absence of agr function75–77,80,201,202. Together,
these results demonstrate the protective benefits of vaccine-induced immune control
of agr type I-regulated virulence. Given that several important pathogens utilize similar
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structurally constrained peptides for virulence regulation203, our findings highlight the
potential clinical utility of VLP-based vaccines targeting virulence regulators as an
alternative or adjunct approach to combat infections caused by other human pathogens.

Results
Presentation of the S. aureus AIP1 sequence on VLPs induces AIP1-recognizing antibodies
We previously found that vaccination with AIP1 (cyclic or linear) chemically cross-linked
to VLPs did not protect mice against subsequent skin infection (unpublished data). This
could have been at least in part due to instability of the AIP thiolactone bond79 resulting in
peptide linearization at some time during the vaccine preparation or vaccination process81.
Therefore, in an effort to promote immunogenicity and maintain the structural integrity of
AIP1 presentation to the adaptive immune system, we inserted a modified AIP1 sequence
to be presented in a highly-constrained β-turn on the surface of VLPs assembled from the
previously reported PP7 single-chain coat protein dimer197–199,204–206 (Figure 2.1 A-C).
The icosahedral capsid of the Pseudomonas aeruginosa RNA bacteriophage PP7 selfassembles from 180 coat protein monomers207,208, whose structural arrangement is
equivalent to 90 coat protein dimers207. Recombinantly-expressed PP7 coat protein selfassembles into stable VLPs consistent in size with the bacteriophage PP7 icosahedral
capsid204,207,209. The highly constrained β-turn within the PP7 coat protein, called the ABloop, is displayed on the surface of the assembled capsid200,207,208 or VLP, and peptides
inserted into this loop are highly immunogenic199,204,209,210. To avoid potential
intermolecular disulfide bond formation via the AIP1 internal cysteine that could
negatively impact VLP purification and immune presentation, the inserted AIP1 sequence
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included a cysteine to serine mutation in position 4 (YSTCDFIM to YSTSDFIM) (referred
to as AIP1S) (Figure 2.1 A). We predicted that this conservative mutation would still allow
vaccine induction of AIP1 specific antibodies given (i) that the cysteine side chain is
confined to the thiolactone bond in the native molecule, and (ii) that presentation of the
AIP1 sequence in the context of the highly constrained PP7 AB-loop would simulate the
cyclic nature of AIP1 in the absence of this labile bond. Recombinantly-expressed PP7AIP1S VLPs resolved into a single peak by size exclusion purification, with agarose gel
electrophoresis showing fractions containing a single protein band co-localizing with
encapsidated RNA, and with homogeneity shown by dynamic light scattering analysis
(Supplemental Figure S2.1). Insertion of the AIP1S sequence into the PP7 single-chain
coat protein dimer was verified by DNA sequencing of the expression plasmid (data not
shown) and by electrophoretic size comparison (Figure 2.1 D). Given that the equivalent
of 90 coat protein dimers are needed to form the PP7 bacteriophage icosahedral capsid,
PP7-AIP1S VLPs produced from PP7 single-chain coat protein dimers with the AIP1S
insertion in the second AB-loop should therefore display 90 copies of AIP1S for immune
stimulation.
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Figure 2.1 - Design and preparation of PP7-AIP1S VLPs. (a) Schematic of AIP1 and
amino acid sequence of AIP1-C4S (AIP1S). (b) Ribbon representation of the PP7 coat
protein dimer (one monomer is shown in green and the other in magenta) which can be
expressed as a single-chain dimer. Depicted is the first AB loop (indicated by arrow) and
the AIP1S sequence (spheres) modeled into the second AB loop (PDB ID 2QUD200) using
GalaxyWeb205,206. Image prepared using PyMOL (PyMOL molecular graphics system,
version 1.5.0.4; Schrodinger, LLC). (c) Schematic of the site of AIP1S insertion into the
second AB loop of the PP7 single chain dimer. (d) Coomassie-stained 16% SDS-PAGE
showing the relative size of the PP7 single-chain dimer compared to PP7 with the AIP1S
insert.
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Supplementary Figure S2.1 - Purification of PP7-AIP1S VLPs. (a) Representative size
exclusion purification of PP7-AIP1S VLPs using a 16/60 Sephacryl S-400 HR column
(chromatogram produced using UNICORN software, GE Healthcare, Pittsburgh, PA).
Arrow indicates fractions analyzed by agarose gel electrophoresis in (b) and (c). (b)
Coomassie (protein) staining and (c) ethidium bromide (EtBr) staining showing VLPencapsulated nucleic acid. (d) Dynamic light scattering analysis of purified PP7-AIP1S in
PBS (Malvern Zetasizer Nano Z, Malvern, UK) showing a major peak consistent in size
with PP7 VLPs and a higher diameter peak consistent with PP7 aggregation (reduced with
low concentration detergent).
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We first sought to determine whether vaccination with PP7-AIP1S would induce
production of antibodies capable of recognizing S. aureus AIP1. To address this, we
vaccinated mice with PP7-AIP1S (twice with a 4-week interlude) and then measured the
ability of serum antibodies to recognize AIP1. Although prior vaccination efforts using
linear or cyclic AIP1 chemically cross-linked to VLPs induced antisera capable of binding
immobilized linear or cyclic AIP1 by ELISA (unpublished data), these vaccines failed to
provide protection during S. aureus infection81, possibly suggesting that antibody
recognition of the AIP linear tail (Figure 2.1 A) or linearized AIP is not sufficient for
protection. Therefore, here we measured antibody binding to AIP1S as presented in the
AB-loop on the surface of PP7, followed by competition binding to soluble, cyclic AIP1.
Serum collected at two-, four- and eight-weeks after the last vaccination with PP7-AIP1S,
but not after PP7 control vaccination, showed dose-dependent binding to the AIP1S
sequence present on PP7-AIP1S VLPs (Figure 2.2 A and Supplemental Figure S2.2).
Importantly, in competitive dose-response assays, AIP1S binding by eight-week postvaccination antiserum (geometric mean titer = 4,550) was inhibited by synthetic cyclic
AIP1, but not synthetic AIP2 (GVNACSSLF) (Figure 2.2 B), demonstrating specificity
and the ability to bind native AIP1. Therefore, these results demonstrate that presentation
of AIP1S, which lacks the native AIP thiolactone bond, within the PP7 AB-loop is
sufficient to elicit antibodies, which recognize soluble, native AIP1.
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Figure 2.2 - PP7-AIP1S vaccination induces antibodies which recognize soluble AIP1.
BALB/c mice were vaccinated twice (i.m.) at 4 week intervals with 10 µg of PP7-AIP1S
or PP7 wild-type (control). (a) Serum was collected at the indicated time points after the
second vaccination. Serum was then pooled (n = 3 mice per group), treated as described in
Materials and Methods, and relative binding to PP7-AIP1S determined by ELISA. (b) PP7AIP1S antiserum collected at eight weeks after the second vaccination was prepared as in
(a), and relative AIP1S binding determined in the presence and absence of the indicated
concentrations of AIP1 or AIP2 (n = 3 mice per group; duplicate experiments performed in
triplicate). Data are mean ± s.e.m. Kruskal-Wallis ANOVA p < 0.0001 with Dunn’s posttest: *p < 0.05; ***p < 0.001.

36

Supplementary Figure S2.2 - AIP1S-specific binding by antisera from individual PP7AIP1S vaccinated mice. Binding to AIP1S by sera from individual mice is shown in black
(dashed lines) (2 weeks), blue (4 weeks) and red (8 weeks). Data are mean ± s.e.m.
Analyses of pooled sera from these groups of mice and from groups of PP7 vaccinated
mice are shown in Figure 2.
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PP7-AIP1S vaccination provides protection in a murine model of S. aureus dermonecrosis
MRSA isolates of the pulsed-field gel electrophoresis type USA300 (agr type I) have long
been the cause of most community-associated MRSA (CA-MRSA) infections, and now
also cause an increasing number of health-care associated infections211. In mouse models
of USA300 SSTI, infection with an isogenic agr-deletion mutant (Δagr) results in
significantly decreased pathogenesis and increased bacterial clearance compared to
infection with the wild-type agr+ strain76,77,80,201,202. Therefore, we postulated that
vaccination with PP7-AIP1S would induce immune suppression of agr-signaling in vivo,
thus reducing pathogenesis and increasing bacterial clearance during SSTI. To evaluate the
efficacy of PP7-AIP1S vaccination against agr type I-mediated virulence and to avoid
potential non-specific effects of VLP administration212, we challenged mice eight weeks
after final vaccination using a well-established mouse model of S. aureus SSTI213 and the
highly virulent USA300 isolate LAC214. As expected, PP7-AIP1S vaccinated mice showed
reduced abscess formation and dermonecrosis over the course of a six-day infection
compared to controls (Figure 2.3 A-D), although differences in weight loss (used as a
measure of morbidity) did not reach statistical significance (Figure 2.3 E). Importantly,
bacterial burden on day 6 post-infection was also significantly reduced in the PP7-AIP1S
vaccinated group compared to both PBS and PP7 controls (Figure 2.3 F). Reduced
bacterial burden was consistent with significantly lower local levels of the inflammatory
cytokines IL-1β, TNFα, IL-1α and IL-17 in PP7-AIP1S vaccinated mice compared to PBS
controls (Figure 2.3 G). However, differences in local levels of these cytokines between
the PP7 WT and PP7-AIP1S groups did not reach significance. In addition, local IL-6
production was significantly reduced in both PP7 WT and PP7-AIP1S vaccinated mice,
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potentially pointing to a non-specific effect of VLP vaccination on pro-inflammatory
cytokine production at this time point. In contrast, significant differences were not
observed in local production of CXCL1 or the anti-inflammatory cytokine IL-10. Together,
these data demonstrate the efficacy of PP7-AIP1S vaccination against S. aureus agr type
I-regulated pathogenesis during skin infection.
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Figure 2.3 - PP7-AIP1S vaccination limits the severity of S. aureus skin infection in a
mouse model of dermonecrosis. BALB/c mice were vaccinated twice (i.m.) at 4 week
intervals with 10 µg of the indicated VLPs or PBS control. Eight weeks after the second
vaccination, mice were challenged by subcutaneous infection with 4 × 107 CFU of USA300
LAC. Representative (a) day 3 images of infection site and (b) daily measures of abscess
area and dermonecrosis. Calculated area under the curve (AUC) values for (c) abscess area
(ANOVA p < 0.0042), (d) dermonecrosis (p = 0.0177) and (e) percent weight change over
the six day infection, as well as (f) day 6 bacterial burden at the site of infection (p = 0.0001)
(representative of two independent experiments of n = 6 mice per group). (g) Cytokine
levels in clarified abscess tissue homogenate on day 6 post-infection (ANOVA IL-1β,
p = 0.0587; TNFα, p = 0.0358; IL-1α, p = 0.0171; IL-17, p = 0.0322; IL-6, p = 0.0010)
(n = 6 mice per group). Data are mean ± s.e.m. Newman-Keuls post test: ns, not significant;
*p < 0.05; **p < 0.01; ***p < 0.001.
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PP7-AIP1S vaccination inhibits S. aureus agr-signaling in vivo
S. aureus agr-signaling induces expression of the effector molecule RNAIII as well as
production of alpha-hemolysin (Hla), the causative agent of dermonecrosis113,117,215–217.
The results of our challenge studies, as well as our in vitro studies showing that antibodies
from PP7-AIP1S vaccinated mice bind soluble AIP1, suggested that vaccination with PP7AIP1S results in immune suppression of agr-signaling during S. aureus SSTI. If correct,
we would expect reduced RNAIII transcription and Hla expression at the site of infection
(local) in PP7-AIP1S vaccinated mice compared to controls. To test this, we measured
local RNAIII expression and Hla protein levels on days one and six, respectively, following
subcutaneous infection. As expected, RNAIII expression was reduced at the site of
infection in PP7-AIP1S vaccinated mice compared to controls (Figure 2.4 A).
Furthermore, day six post-infection Hla levels were reduced in PP7-AIP1S vaccinated mice
relative to PBS controls (Figure 2.4 B-C), although differences between PP7-AIP1S
versus PP7 WT vaccination were not statistically significant. Together, these data support
a mechanism of action whereby vaccination with PP7-AIP1S induces immune control of S.
aureus agr type I signaling and virulence regulation during SSTI.
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Figure 2.4 - PP7-AIP1S vaccination limits agr function at the site of S.
aureus infection. BALB/c mice were vaccinated twice (i.m.) at 4 week intervals with 10 µg
of the indicated VLPs or PBS control. Eight weeks after the second vaccination, mice were
challenged by subcutaneous infection with 4 × 107 CFU of USA300 LAC. (a) Local
RNAIII transcription on day 1 post-infection measured by qPCR (n = 4 mice per group,
Kruskal-Wallis ANOVA p = 0.0029). (b) Representative immunoblot (showing
recombinant Hla, MW marker and 3 mice per group) and (c) quantification of Hla levels
(relative to PBS control) in clarified abscess tissue homogenate on day 6 post-infection
(n = 6 mice per group) (Kruskal-Wallis ANOVA p = 0.0025) with Dunn’s post-test: ns, not
significant; *p < 0.05; **p < 0.01.
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Discussion
The ongoing antibiotic resistance crisis highlights the urgent need for non-conventional
approaches to combat infectious disease, including approaches to inhibit bacterial
virulence60,176. In the case of the important human pathogen Staphylococcus aureus,
virulence regulation is largely mediated by the agr operon via secretion of AIPs65,193. These
small, conformationally-restrained, secreted peptides bind in an autocrine and paracrine
fashion to the bacterial membrane receptor AgrC, which in turn regulates downstream
virulence factor expression. Therefore, antibody-mediated sequestration of secreted AIPs
could neutralize agr-signaling and virulence factor expression on a population level. Of the
four S. aureus agr types, agr type I isolates are most frequently associated with invasive
infection83,195. Here we report that multivalent, conformationally-restricted presentation of
a modified AIP1 amino acid sequence on VLPs elicits immune control of S. aureus
agr type I-regulated virulence. Specifically, PP7-AIP1S vaccination (1) induced the
production of anti-AIP1 antibodies, (2) limited agr type I-signaling in vivo and (3)
demonstrated efficacy (reduced pathogenesis and increased bacterial clearance) in a mouse
model of S. aureus SSTI. Given these results and the contribution of agr type I isolates to
human S. aureus infection83,195, vaccine prevention of agr type I-mediated virulence could
have a major clinical impact and make a significant contribution to the fight against
antibiotic resistance.
The diversity of virulence factors produced by S. aureus192, many of which disable
innate immune cells218–220, and the range of infection types (skin, pneumonia, bacteremia,
etc.)192,221, suggests that multiple anti-virulence approaches may be needed to limit human
disease. For example, targeting specific virulence factors, in particular Hla which is a major
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contributor

to

pathogenesis113,

has

shown

efficacy

in

numerous

animal

models117,124,140,143,144,216 and a monoclonal antibody targeting Hla (MEDI4893) is
currently in human clinical trials222. Broader approaches aimed at inhibiting S.
aureus virulence regulation have included peptide and small molecule targeting of
the agr system69,75,76,80,87,90,223–232, as well as development of a monoclonal antibody (mAb)
against S. aureus AIP479,233. However, agr-signaling has been shown to occur early postinfection and disruption of this early signaling correlates with reduced pathogenesis in the
host76, suggesting a possible limit to the window of opportunity for therapeutic agrinhibition. Therefore, the development of an efficacious anti-agr vaccine could expand the
impact of S. aureus virulence regulation strategies to have the broadest potential clinical
benefit to patients. In this regard, we previously developed a VLP-based AIP4 mimotope
vaccine by screening a VLP-peptide library against an anti-AIP4 mAb, AP4-24H1179,81,233,
shown by passive transfer to be protective in a mouse model of agr type IV SSTI. Here we
advance this work by demonstrating the efficacy of PP7-AIP1S vaccination against S.
aureus agr type I-regulated virulence using the highly virulent CA-MRSA USA300 isolate
LAC214. While it will be important in future work to expand these studies to include
infections using other agr type I isolates versus isolates of heterologous agr types, our in
vivo results, together with in vitro data demonstrating that PP7-AIP1S elicited antibodies
bind soluble AIP1, but not soluble AIP2, suggest that protection afforded by PP7-AIP1S
vaccination is specific to agr type-I regulated virulence. Therefore, this VLP-based
approach may be utilized to produce a combined vaccine against virulence regulation by
each of the agr types, thus serving as a valuable component of an overall anti-virulence
strategy.

44

In addition to Staphylococcal species65,193, other human pathogens using agr-like
quorum sensing systems and secreted peptides to coordinate virulence factor
expression203 could be targeted by VLP-based vaccination. For example, the food-borne
pathogen Listeria monocytogenes uses a variety of communication systems to regulate
virulence234,235, including an agr locus and recently identified secreted AIP236–240. In L.
monocytogenes, the agr system regulates over 650 genes contributing to virulence
including

ones

involved

in

biofilm

formation

and

host

cell

invasion237.

Similarly, Enterococcus faecalis, an important cause of drug resistant infections241, uses
the agr-like fsr gene locus and the secreted, cyclic peptide gelatinase biosynthesisactivating pheromone (GBAP)242,243 to regulate expression of virulence factors important
for biofilm formation and pathogenesis244–249. Importantly, it has also recently been shown
that an agr locus regulates production of toxins A and B by the multidrug resistant
pathogen Clostridium difficile250,251. These C. difficile toxins are directly responsible for
disease manifestation252 which, in severe cases, can result in sepsis and death253, suggesting
that interference with agr-signaling by this pathogen could significantly limit disease.
Therefore, a VLP-vaccine platform could provide a straight-forward approach to elicit
immune inhibition of agr- and agr-like virulence signaling by these and other important
human pathogens.
While vaccine targeting of S. aureus agr-regulated virulence has clear benefits,
potential limitations have also been noted194,254,255. For example, in vitro studies have
shown an isolate-dependent association between deletion of agr and increased biofilm
formation, raising the possibility that inhibiting agr in vivo could promote biofilms256–258.
Increased in vitro biofilm formation by agr deletion mutants is attributed to increased
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expression of genes encoding surface associated factors, such as protein A and the
fibronectin binding proteins (FnBPs), in parallel with down regulation of secreted virulence
factors which promote biofilm dispersal80,192,259–262. However, agr-regulated factors can
inhibit phagocyte clearance of S. aureus in biofilms263, suggesting that targeting agr in
vivo may also support host innate defense against biofilm infections. A second concern
regarding in vivo inhibition of agr is whether this will select for agr mutants. Although
most clinical isolates of S. aureus are agr positive, isolates with mutations in agr can arise
naturally during chronic infections195,264,265. However, whether antibody-mediated
inhibition of AIP is more likely to select for agr mutants than host innate effectors which
antagonize agr-signaling, such as apolipoprotein B (apoB)201,202, hemoglobin266 and
reactive oxygen species267, has yet to be addressed. Given the contribution of agr to S.
aureus pathogenesis and the protection afforded by vaccine targeting of AIPs, the
potential in vivo impact of this approach on both S. aureus biofilm formation and the
selection of agr mutants are important areas for future investigation.
Virus-like particles have proven to be a flexible and highly immunogenic platform
for vaccine design, and are currently used in FDA-approved vaccines183, including
Hepatitis B vaccines268 and the current nonavalent HPV vaccine (Gardasil 9) designed to
induce protection against nine HPV types181. Although non-replicating, the dense,
repetitive array of coat proteins comprising VLPs is largely unique to microbial antigens
and this multivalency triggers a robust immune response in mammals. Therefore, VLPs
can dramatically increase the immunogenicity of otherwise poorly immunogenic
peptides177,186 including self-antigens269,270. This property, along with the potential for
presentation of conformation-dependent antigens, has resulted in investigation of VLP46

based vaccines against numerous pathogenic viruses, allergies, cancer, autoimmune
disease, Alzheimer’s disease and chronic diseases such as hypertension177,271–274. However,
reports of the use of VLP-based vaccines to elicit adaptive immunity against specific
bacterial pathogens or proteins have come mainly from our own work81 and from research
targeting Streptococcal species275–277, suggesting that the flexibility of VLP-based vaccine
approaches to address bacterial diseases remains largely untapped. Given the FDA
approval and success of VLP vaccines against viral pathogens, the use of VLP-based
vaccines to prevent infections by the many important human bacterial pathogens warrants
further investigation.
In this era of diminishing antibiotic efficacy, a multi-pronged approach, including
novel antibiotics, host-targeted therapeutics, vaccines, anti-virulence strategies and
combined therapies will likely be crucial for combating disease caused by antibiotic
resistant pathogens60,176,194,278. Here we present a novel approach to achieve vaccine
induced immune control of S. aureus agr-regulated virulence. This work highlights the
potential clinical utility of VLP-based vaccines as part of an overall strategy to combat
infections caused by MRSA and other important antibiotic resistant human pathogens
utilizing secreted peptides for virulence regulation203.

Materials and Methods
Ethics Statement
Animal studies described herein were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of New Mexico Health Sciences Center (Animal
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Welfare Assurance number D16-00228) and conducted in strict accordance to
recommendations in the Guide for the Care and Use of Laboratory Animals279, the Animal
Welfare Act, and U.S. federal law.

Bacterial strains and growth conditions
The CA-MRSA USA300 isolate LAC214 (generously provided by Dr. Frank DeLeo, Rocky
Mountain National Laboratories, National Institutes of Health, Hamilton, MT) was used
for infection studies. Early exponential-phase bacteria were prepared as previously
described280 and stored at −80 °C for no more than two weeks prior to use. For infection
studies, bacteria were diluted in USP-grade saline (B. Braun Medical, Irvine, CA) to yield
4 × 107 CFU per 50 µL. The number of CFU was verified by plating ten-fold serial
dilutions onto Trypticase soy agar containing 5% sheep blood (Becton, Dickinson and
Company; Franklin Lakes, NJ).

VLP cloning, expression and purification
The pDSP7K plasmid281, encoding the PP7 single-chain dimer under the T7 promoter and
transcription terminator, was used for synthesis of PP7-AIP1S VLPs in E. coli. With
pDSP7K as a template, PCR was used to produce an insert fragment encoding a KpnI
restriction site, the modified AIP1 sequence (YSTSDFIM), and a downstream BamHI site
(forward primer 5′-GGC GGT ACC TAC AGT ACC TCT GAC TTC ATC ATG GAG
GCT ACT CGC ACT CTG ACT GAG-3′; reverse primer 5′-CGG GCT TTG TTA GCA
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GCC GG-3′). The PCR fragment was inserted into the pDSP7K at the KpnI and BamHI
restriction sites and insertion was verified by sequence analysis.
E. coli C41 cells (Lucigen, Middleton, WI) transformed with pDSP7K or the
pDSP7K-AIP1S expression plasmids were grown at 37 °C to an OD600 of 0.8. Expression
was induced with 1 mM IPTG, cells cultured for an additional 3 hours, and harvested by
centrifugation. Cell pellets were lysed and VLPs purified essentially as described
previously199 but with size exclusion purification using a 16/60 Sephacryl S-400 HR
column (GE Healthcare, Pittsburgh, PA). VLP purity was verified by SDS-PAGE and
agarose gel electrophoresis plus Coomassie and ethidium bromide staining. VLPs were
concentrated using Amicon Ultra Centrifugal filter units (100 K MWCO) (EMD Millipore,
Billerica, MA), and concentrations determined by SDS-PAGE comparison to hen egg
lysozyme concentration standards (Sigma-Aldrich, St. Louis, MO). Homogeneity was
based on modality analysis using a Malvern Zetasizer Nano Z (Malvern, UK). VLP aliquots
were stored at −20 °C until use.

Mouse immunizations
Four week old, female BALB/cJ mice (Jackson Laboratories, Bar Harbor, ME, USA) were
immunized by injection into the caudal thigh muscle with 50 µL of PBS alone or containing
10 µg of either PP7-AIP1S or PP7. Mice received an identical injection four weeks after
the initial dose. Serum for ELISA analysis was collected by cardiac puncture at two, four
or eight weeks after the second vaccination, with challenge experiments performed at the
eight week time-point.
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ELISA
ELISA plates to measure serum antibody binding to AIP1S were prepared by coating Ultra
Cruz ELISA High Binding plates (Santa Cruz Biotechnology, Santa Cruz, CA) with 125 ng
per well of recombinant PP7 or PP7-AIP1S in 50 µL PBS and incubating 20 hours at room
temperature (RT) with shaking. After removing excess liquid, plates were blocked for
2 hours with PBS containing 0.05% Tween-20 and 1% casein. To reduce PP7- and
potential E. coli-binding antibodies (depleted serum) mouse serum was treated as follows:
Serum was diluted 1:50 in PBS and incubated for one hour at RT with end-over-end
rotation together with recombinant PP7 (10 µg per 300 µL diluted serum) and PBS-washed
C41 cells (the E. coli strain used for VLP-expression) (~9 × 106 CFUs). The mixture was
centrifuged (5 min at 11,600 × g) to remove antibody bound to C41 cells, and the
intermediate depleted serum processed through an Amicon Ultra Centrifugal filter unit
(100K MWCO) to remove antibody bound to PP7. The presence of antibody in the filtrate
(depleted serum) was verified by SDS-PAGE and Coomassie staining. The final depleted
serum was serially diluted onto PP7- or PP7-AIP1S-coated ELISA plates and incubated for
1 hour at RT. Murine antibodies bound to VLPs were detected using goat anti-mouse polyHRP secondary antibody (ThermoFisher Scientific, Waltham, MA) and developed using
1-Step™ Ultra TMB-ELISA according to manufacturer’s directions (ThermoFisher
Scientific). For each serum sample and dilution, AIP1S specific binding (ΔA450) was equal
to the A450 for PP7-AIP1S binding minus the A450 for PP7 binding. For competition
ELISAs, depleted serum was incubated for 1 hour at 37 °C with the indicated
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concentrations of AIP1 or AIP2 (BioPeptide Co., Inc., San Diego, CA) before addition to
PP7-AIP1S-coated ELISA plates.

Mouse skin infection model
The mouse model of dermonecrosis was implemented essentially as previously
described213. One to three days before infection (eight weeks after the second vaccination),
Nair™ was used to depilate the right flank of the mice (site of infection). On the day of
infection, mice were anesthetized by isoflurane inhalation and infected by subcutaneous
injection of 50 µL of saline containing 4 × 107 CFU of LAC. Mice were weighed the day
of injection and daily thereafter until sacrifice. Injection sites were photographed daily and
abscess and dermonecrosis areas determined by analysis with ImageJ282. Six days after
infection, mice were sacrificed by CO2 asphyxiation and a 2.25-cm2 section of skin
surrounding the abscess was excised for mechanical disruption. Abscess homogenate was
serially diluted and plated on sheep blood agar to determine infection site bacterial burden.
The remaining homogenate was clarified by centrifugation and the clarified fraction stored
at −80 °C until cytokine analysis.

Cytokine analysis by multiplex assay
Clarified abscess tissue homogenates were quick thawed at 37 °C and concentrations of the
indicated cytokines determined using a BioPlex 200 system and BioPlex manager software
(Bio-Rad, Hercules, CA) together with a custom-designed mouse multiplex assay (EMD
Millipore, Billerica, MA) according to manufacturer’s directions.
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RNA isolation from tissue and quantitative PCR analysis
For analysis of day one post-infection bacterial gene transcription, 2.25 -cm2 sections of
skin surrounding the infection site were harvested, minced, and stored in
RNAlater (Qiagen, Valencia, CA) at −20 °C. RNA was isolated using QIAzol (Qiagen)
and purified using RNeasy kits (Qiagen) according to manufacturer’s directions. cDNA
conversion from RNA was performed with a High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA) and specific primers for S. aureus 16S (reverse,
5′-TTC

GCT

CGA

CTT

GCA

TGT

GATGTTGTTTACGATAGCTTACATGC-3′)

or

RNAIII

(Integrated

DNA

A-3′)

(reverse,

5′-

Technologies,

Coralville, IA). Quantitative PCR (qPCR) was performed using a ViiA-7 RT-PCR system
(Applied Biosystems), the specific primers and probes201 for 16S (forward primer, 5′-TGA
TCC TGG CTC AGG ATG A-3′; reverse primer above and probe 5′-CGC TGG CGG CGT
GCC TA-3′) and RNAIII (forward primer, 5′-AAT TAG CAA GTG AGT AAC ATT TGC
TAG T-3′; reverse primer above and probe 5′-AGT TAG TTT CCT TGG ACT CAG TGC
TAT GTA TTT TTC TT-3′) (Integrated DNA Technologies) and TaqMan Gene
Expression Master Mix according to the manufacturer’s protocol (Applied Biosystems).
Data are shown as the fold expression of RNAIII versus 16S and relative to the PBS
control.

Tissue Hla quantification by Western blot
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For Western blot analysis of Hla levels in clarified abscess homogenate, frozen samples
were quick thawed and equal amounts of total protein (based on A280) were electrophoresed
on 16% Tris-glycine SDS-PAGE gels (Life Technologies, Grand Island, NY). Following
transfer to polyvinylidene fluoride membrane, membranes were blocked overnight at 4 °C
with TBST (20 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween 20) with 5% nonfat dry milk.
Hla was detected using sheep anti-Hla primary antibody (ab15948, Abcam, Cambridge,
MA) and alkaline phosphatase-conjugated rabbit polyclonal anti-sheep secondary.
Membranes were developed with nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3indolyl-phosphate (BCIP) (Thermo Scientific). Band intensity relative to recombinant Hla
control was measured on a FluorChem R system using AlphaView software
(ProteinSimple, San Jose, CA).

Statistical analysis
GraphPad Prism version 5.04 (GraphPad Software, San Diego California) was used for all
statistical evaluations. One-way ANOVA parameters followed Bartlett’s test for equal
variances and were used with Bonferroni’s (ANOVA) or Dunn’s (Kruskal-Wallis test, nonparametrics) post-hoc multiple comparison analyses. Results were considered statistically
significant at p < 0.05.
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Abstract
The key pore-forming cytotoxin α-hemolysin, or Hla, promotes multiple types of
Staphylococcus aureus infection by causing tissue damage, excessive inflammation, and
lysis of both innate and adaptive immune cells, among other cellular targets. Considering
the failures of S. aureus vaccines in clinical trials to date, novel approaches may prove
more efficacious than traditional means. Virus-like particles (VLPs) are a highly versatile
vaccine platform that allow for heterologous display of short peptide epitopes in a
multivalent array, often promoting the induction of a high titer and long-lasting antibody
response. In the present study, we describe the first VLP-based vaccines targeting Hla,
which display a 21 amino acid linear neutralizing domain (LND). Vaccination with either
of two VLP-LNDs protected both male and female mice from subcutaneous Hla
challenge, evident by reduction in lesion size and neutrophil influx to the site of
intoxication. Antibodies induced by VLP-LND vaccines bound both the LND epitope and
the native toxin, effectively neutralizing Hla and preventing toxin-mediated lysis of target
cells. These VLP-LND vaccines are the first to target the Hla 119-139 domain by active
vaccination. We anticipate these novel and promising vaccines being single components
to a multi-component S. aureus vaccine to reduce severity of infection.

Keywords: Staphylococcus aureus, α-hemolysin, linear neutralizing domain, virus-like
particles, vaccine, mice

Key Contribution: This work demonstrates that virus-like particle-based vaccines
presenting a neutralizing epitope of S. aureus α-hemolysin may prove useful as part of a
combination vaccine to limit pathogenesis in humans resulting from S. aureus infection.
56

Introduction
The pore-forming toxin α-hemolysin, or Hla, is a key secreted cytotoxin responsible for
much of the pathogenesis of Staphylococcus aureus, playing an important role in skin and
soft tissue infection (SSTI), pneumonia (PNA), and many others118,128,283–290. Hla
associates with its host cell receptor, ADAM10, and creates pores resulting in cell lysis,
which further results in tissue damage and excessive inflammation mediating
pathogenesis111. For these reasons, Hla is a mediator of S. aureus infection and therefore
neutralizing Hla has been the focus of numerous interventions. Hla has been the target of
active vaccines117,124,140,141 and monoclonal antibodies130,291, both methods showing
success in preclinical animal studies. However, the therapeutic window of protection by
passive transfer of antibodies against S. aureus is not well defined, and active vaccines thus
far have not been successful in humans. Therefore, novel approaches against S. aureus may
be more successful.
An emerging vaccine platform are those based on epitope display by virus-like particles
(VLPs). VLPs are composed of viral coat protein yet non-replicative and non-pathogenic
due to lacking the viral genome from which the capsid was derived177. Bacteriophage VLPs
are an immunogenic and versatile platform allowing the multivalent display of virtually
any epitope, which results in a high titer, long lasting antibody response185. Furthermore,
VLP-based vaccines have been shown to be safe in humans (see FDA-approved Gardasil,
Cervarix, and Gardasil9178, and other phage-based VLPs in clinical trials292,293). Although
VLP-based vaccines have shown success in many different areas ranging from infectious
disease to autoimmune disorders179–182, VLPs have not yet been developed targeting S.
aureus toxins. We took advantage of this versatile platform to develop a vaccine targeting
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an Hla linear neutralizing domain (LND) first identified by Oscherwitz and Cease143
(Figure 3.1 A), to which passive transfer of neutralizing antibodies protected mice from
Hla-mediated pathogenesis.
We designed two candidate VLP-based vaccines for the display of the Hla-LND
epitope, utilizing either genetic fusion or chemical crosslinking. The AP205 VLP platform
is derived from the viral coat protein of the RNA bacteriophage AP205, which infects
Acinetobacter sp. and is tolerant of peptide insertions of variable complexity and sequences
of up to at least 55 amino acid residues in length in either the N- or C-termini294. The 21
amino acid LND epitope was genetically inserted at the C-terminal end of the AP205 coat
protein, which has been named “AP205-LND” (Figure 3.1B). A second LND-displaying
VLP was created by chemically conjugating an LND epitope to the surface of Qβ, a VLP
derived from the coat proteins of the bacteriophage Qβ, which targets Escherichia coli295,
which was named “Qβ-LND” (Figure 3.1C). These AP205 and Qβ VLP platforms were
selected for display of the LND epitope because both allow for multivalent display of the
epitope in an unconfined, linear conformation, which should promote molecular mimicry
to the native conformation of the linear domain in the Hla β-pore.
Here we report the first two VLP-based vaccines to target Hla, which expand on the
study by Oscherwitz and Cease143 by also being the first active vaccines targeting the HlaLND epitope. Vaccination with either VLP-LND protects both male and female mice from
Hla challenge and demonstrates a mechanism of action of Hla neutralization. These
vaccines could become part of a multi-component vaccine to prevent S. aureus infection.
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Figure 3.1 - Schematic of VLPs Displaying Hla LND. (A) (Left) Ribbon depiction of
Hla heptameric pore based on 3ANZ.pdb. Monomers are shown in different colors and
LND region shown as spheres. (Right) Ribbon depiction of Hla monomer with LND region
shown as spheres. Figures produced using PyMOL (The PyMOL Molecular Graphics
System, Version 2.0 Schrödinger, LLC.) (B) (Top left) Linear schematic depicting wild
type AP205 coat protein with C-terminal linker; (top right) schematic of assembled AP205
wild type VLP; (Bottom left) linear schematic of AP205 coat protein with Hla-LND
sequence genetically inserted; (bottom right) schematic of assembled AP205-LND VLP
created through molecular cloning. (C) (Left) schematic of assembled Qβ wild type VLP
depicting surface exposed lysines; (center) linear depiction of succinimidyl 6-[(betamaleimidopropionamido) hexanoate] (SMPH) crosslinker and synthetic CGGG-Hla-LND
prior to chemical conjugation to surface lysines; (right) schematic of assembled Qβ VLP
displaying surface lysine conjugated LND peptides.
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Results
Validation of VLP-LND Vaccines
Recombinant wild type AP205, AP205-LND, and Qβ were expressed in E. coli and
purified using methods previously described296. The presence of peptide insert in the
AP205 coat protein was confirmed with sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS PAGE) by comparing the size of AP205-LND with wild type AP205
(Supplementary Figure 3.1 A). One potential advantage that conjugation to Qβ may
provide is an increased valency compared to AP205, where greater than one peptide
epitope is conjugated to a single Qβ coat protein. However, LND epitope valency between
VLP-LNDs was similar, with approximately 1.05 LND epitopes displayed on Qβ,
compared to one epitope per AP205 coat protein (Supplementary Figure 3.1 A). We
therefore did not expect enhanced antibody response to either VLP-LND vaccination due
to differences in antigenic valency. Agarose gel electrophoresis, which can be used to
identify nucleic acid encapsidated by assembled VLPs296, confirmed the assembly of
AP205-LND and Qβ-LND (Supplementary Figure 1 B).
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Supplementary Figure S3.1 - Validation of AP205-LND and Qβ-LND VLPs. (A) SDS
PAGE showing protein bands for monomers of (left) AP205 and AP205 with LND
genetically incorporated, or (right) Qβ and Qβ chemically conjugated to Hla LND peptide.
(B) Agarose gels stained with ethidium bromide, showing encapsidation of RNA or with
coomassie showing VLP coat protein colocalization with encapsidated RNA for intact
AP205-LND VLPs and Qβ-LND VLPs (left and right, respectively).
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Vaccination with VLPs Displaying LND Epitope Induce Antibodies Recognizing Hla
To determine if VLP-LND vaccination induces the production of antibodies recognizing
full-length Hla, male BALB/c mice were vaccinated and boosted with either AP205-LND,
Qβ-LND, or wild type VLPs (AP205 or Qβ) which was used to control for immunity
against the platforms. To investigate the induction of antibodies against Hla from VLPLND vaccination and the effect of boosting, we tested sera collected pre- and post-boost in
an enzyme-linked immunosorbent assay (ELISA) against plated recombinant
Hla. As expected, sera from mice vaccinated with AP205-LND and Qβ-LND contained
antibodies recognizing rHla, whereas rHla-binding from sera of control-vaccinated mice
was not detectable above background (Figure 3.2 A). Hla titer was detectable in individual
mice after only a single vaccination, with boost enhancing the titer (Figure 3.2 B).
Interestingly, there was no significant difference in anti-Hla titer between AP205-LND or
Qβ-LND vaccination, suggesting no enhanced immunogenicity from increased rigidity
from the protein linker in AP205-LND. These data demonstrate both VLP-LND vaccines
induce antibodies recognizing Hla, suggesting the LND epitopes displayed on the surface
of the VLPs exhibits molecular mimicry to the target domain of the full-length toxin.
To investigate molecular mimicry between VLP platforms, we performed a peptide
ELISA using mouse VLP-LND antisera, where antibody titer to synthetic, conjugated LND
peptide was determined. The LND:full-length Hla titer ratio in individual mice was
determined to be not statistically different with AP205-LND versus Qβ-LND vaccination,
demonstrating the LND epitopes displayed on either platform exhibit no enhanced
molecular mimicry to the target epitope in the full length Hla in its native conformation
(Figure 3.2 C). Overall, these data demonstrate both AP205-LND and Qβ-LND
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vaccination induce the production of antibodies that bind Hla with no difference in binding
ability between them to the native full-length toxin.
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Figure 3.2 - Antibodies Induced from VLP-LND Vaccination Recognize Recombinant
Hla. (A) Antibody binding to Hla from pooled serum from n=8 male BALB/c mice
vaccinated with AP205-LND (n=2 technical replicates) or Qβ-LND (n=2 technical
replicates) at two weeks post-boost, tested by ELISA. (B) Anti-Hla IgG antibody titers
from individual male mice determined by ELISA 4 weeks post-prime (n=8, 7) or 2 weeks
post-boost (n=16, 15). (C) Ratio of anti-LND antibody titer over anti-Hla titer using serum
from male BALB/c mice vaccinated with AP205-LND (n=8 biological replicates) or QβLND (n=7). All antibody titers are reported as the reciprocal of the highest serum dilution
with an OD450 2-fold greater than naïve sera.
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Vaccination with VLP-LNDs Protects from Hla Intoxication Challenge
With the discovery that both VLP-LND vaccines induce antibodies binding Hla, we next
wanted to determine if VLP-LND vaccination provides protection from Hla-mediated
pathogenesis in vivo. To determine this, vaccinated male or female BALB/c mice were
challenged with recombinant Hla injected subcutaneously. As expected, lesion size was
significantly reduced in both AP205-LND- and Qβ-LND-vaccinated mice compared to
control mice over the course of a three-day challenge (Figure 3.3A-C). We asked whether
the lesion size in Hla-challenged mice was dependent on individual induction of an Hla
antibody titer. To test this, we collected sera from Hla-challenged mice and performed an
ELISA to determine individual Hla titers. As expected, lesion area during the challenge
correlated with the log of α-Hla titer in individual mice vaccinated with VLP-LNDs
(Figure 3.3 D), which suggests the mechanism of protection as the induction of an antiHla antibody response.
Furthermore, anti-Hla antibodies were detected at the site of intoxication as
determined by Hla ELISA using lesion homogenate of Hla-challenged vaccinated mice
(Figure 3.3 E). These data demonstrate the efficacy of AP205-LND and Qβ-LND in
protecting mice from Hla-mediated pathogenesis via an induced anti-Hla humoral response
that infiltrates directly to the site of intoxication.
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Figure 3.3 - Vaccination with VLPs displaying LND protects mice from lesion
formation caused by subcutaneous Hla challenge. (A) (Left) Lesion area over the course
of a 3-day Hla intoxication of vaccinated or mock-vaccinated male BALB/c mice (1.25 µg
Hla/mouse). (Right) Calculated lesion area under the curve (AUC) for the 3-day Hla
challenge. (B) (Left) Lesion area over the course of a 3-day Hla intoxication of female
BALB/c mice (2 µg Hla/mouse). (Right) Calculated lesion AUC for the 3-day Hla
challenge. (C) Representative images of external lesions of vaccinated Hla-challenged
male BALB/c mice at day 3 post-intoxication. Scale bar = 5 mm. (D) Linear regression
plot comparing lesion AUC for a 3-day Hla challenge of male BALB/c mice vaccinated
with AP205-LND (n=7 mice/group) or Qβ-LND (n=6 mice/group) versus the log α-Hla
titer, p=0.0070. (E) ELISA showing Hla binding by antibodies from day 3 postintoxication pooled lesion homogenate collected from male BALB/c mice previously
vaccinated with AP205 (n=8 mice/group), AP205-LND (n=7 mice/group), Qβ (n=7
mice/group), or Qβ-LND (n=5 mice/group). (A-B) Data are mean ± SEM for (A) N=16, 8,
7, 7, 6 mice per group and (B) N=8 mice/group. One-Way ANOVA p<0.0001, Tukey’s
multiple comparisons test; ns, not significant; **, p<0.01, ***, p<0.001, ****, p<0.0001.
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VLP-LND Vaccination Limits Inflammatory Response to Hla Challenge
We hypothesized that enhanced neutralization of Hla during an in vivo Hla challenge would
result in reduced local neutrophil efflux and inflammation. To test this, we performed a
histological assessment of lesions collected from vaccinated mice challenged with Hla.
Lesions in VLP-LND-vaccinated mice exhibited clearly reduced inflammation and tissue
damage compared to lesions of control-vaccinated mice, which displayed a neutrophilic
barrier crossing the dermis and epidermis surrounding the intoxication site (Figure 3.4).
This suggests VLP-LND vaccination limits the proinflammatory response to Hla
challenge.
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Figure 3.4 - VLP-LND Vaccination Limits Tissue Damage and Inflammatory
Response to Hla Challenge. H&E stained Hla-intoxicated skin sections collected 3-days
post-intoxication from vaccinated male BALB/c mice. Arrowheads denote neutrophilic
barrier around intoxication site. Scale bar = 0.5 mm.
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AP205-LND Vaccination Induces Hla-Neutralizing Antibodies
VLP-LND vaccination induced antibodies that bind Hla and provide protection from Hlamediated pathogenesis. To further confirm the ability for VLP-LND-induced antibodies to
neutralize Hla and prevent lysis of target cells, we performed a toxin neutralization assay
as previously described143, where sera collected from BALB/c mice vaccinated with AP205
or AP205-LND as described above was tested for its ability to prevent Hla-mediated lysis
of Jurkat cells, a human T lymphocyte line and natural target of Hla. AP205-LND antisera,
and not AP205 antisera, demonstrated significant neutralization of Hla in preventing Jurkat
cell lysis (Figure 3.5). These data demonstrate that antisera from AP205-LND vaccination
directly neutralizes Hla and protects target cells from Hla mediated lysis.
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Figure 3.5 - VLP-LND vaccination elicits antibodies which protect against Hlamediated pathogenesis in vitro and in vivo. Toxin neutralization assay measuring
viability of Jurkat cells incubated with 0.8 µg/mL Hla combined with sera collected from
vaccinated mice diluted 1:12. Sera include pooled naïve BALB/c serum (n=5 mice/group),
naïve serum spiked with ~9 μg/mL Hla-neutralizing mAb 8B7 (IBT #0210-001), and
pooled serum from mice vaccinated with AP205wt (n=3 mice/group) or AP205-LND (n=3
mice/group). Assay performed in triplicate. A450 values were normalized to a total lysis
control (RPMI+0.1% Triton-X114) set to 0% neutralization and a no lysis control (RPMI)
set to 100% neutralization. One-way ANOVA p<0.0001. Sidak’s multiple comparison test;
***, p<0.001; ****, p<0.0001.
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Discussion
Novel and effective treatment options are urgently needed to combat Staphylococcus
aureus, as the prevalence of drug-resistant S. aureus isolates, such as the methicillinresistant S. aureus (MRSA) strains, increases and the list of effective antibiotics shortens60.
Although no vaccine developed thus far targeting S. aureus has successfully passed phase
III of clinical trials191,297–299, the failed vaccines share a common feature: the attempt to
induce an antibody response against S. aureus surface targets for opsonophagocytic
clearance of the bacteria297. Since these failures, there has grown a better understanding of
how S. aureus evades immune-mediated opsonophagocytic killing by expression of
surface-displayed proteins such as staphylococcal protein A (SpA) and staphylococcal
binder of immunoglobulin (Sbi), which bind antibodies by the Fc region, preventing
antibody-mediated clearance of S. aureus13,152,153. However, there is a body of work
supporting the argument that infection severity can be reduced by high neutralizing
antibody titers against secreted toxins155, including Hla, a key S. aureus cytotoxin and
promoter of infection120,121. The foundation of this concept is that the innate immune cells
responsible for initial host defense and invasive infection prevention against S. aureus
(keratinocytes, epithelial cells, neutrophils, and monocytes/macrophages)45,300, are the
targets of pore-forming toxins such as Hla113; therefore, toxin neutralization should
enhance natural host defense mechanisms and limit infection severity. Decreased
phagocyte numbers due to functional defects in patients increases incidence of S. aureus
infection45,301,302. In addition, human clinical data suggests boosting a neutralizing Hla titer
alone may provide protection in several types of S. aureus disease, as high titer of
antibodies targeting Hla were found to correlate with decreased severity of S. aureus
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sepsis120 in adults and reduced recurrence of S. aureus SSTI in children121. In the present
study, we characterized the host antibody response directed to two novel vaccines targeting
Hla, which are the first active vaccines targeting the LND epitope.
Hla plays a particularly important role in dictating severity in many types of
infection in animal models including pneumonia118,283, SSTI128,284, sepsis285,286,
peritonitis284, and others287–290. Furthermore, S. aureus strains not expressing Hla are
poorly virulent116, yet USA300 strains, which express Hla at a high level, are hypervirulent119. Therefore, Hla has been a highly desirable target for therapeutic and
prophylactic targeting and is considered a promoter of infection. Active vaccines targeting
Hla have shown success in preclinical animal models of pneumonia124,128,140,142,
SSTI128,141,143,144, and bacteremia140, all of which are models of S. aureus infection where
Hla is known to play a large role in mediating pathogenesis118,128,283–286. Such Hla vaccines
include a toxoid vaccine with an H35L mutation disabling the toxin’s cytolytic
ability124,128,142, Hla toxoid with a double mutation (H35L/H48L)142, or a vaccine
incorporating an Hla N-terminal subunit (AT62)140,141. Passive immunization with
suvratoxumab (MEDI4893), a monoclonal antibody targeting the N-terminal region of Hla,
has also been shown to limit pathogenesis in murine models of dermonecrosis131,138,139,
pneumonia132,133,138, and sepsis136,138. To the best of our knowledge, the vaccines described
in the present study are the first active vaccines targeting this linear neutralizing domain of
Hla (119-131)143 and providing neutralizing immunity against Hla toxicity. Comparison
experiments alongside existing Hla vaccines and monoclonal antibodies should be
performed to determine if our VLP platform provides an advantage in antibody titer,
avidity, or longevity. Although, efficacy for a duration greater than the testing period in
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the present study of 84 days after initial vaccination has not been shown by other Hla
vaccines. Additionally, both VLP-LND vaccines must be tested further in S. aureus
infection models such as SSTI, pneumonia, and sepsis, to further demonstrate vaccine
utility in reducing infection severity. However, considering Hla is one of many secreted
virulence factors used by S. aureus to cause pathogenicity during infection21, we foresee
the greatest utility of the VLP-LND vaccines in being a single component of a multicomponent S. aureus vaccine targeting many virulence factors. In a recent study, increased
vaccine efficacy was shown by neutralizing multiple virulence factors, targeting the poreforming Panton-Valentine leucocidin (PVL) in addition to Hla, which further enhanced
protection in a rabbit model of necrotizing pneumonia142. And finally, although these
proof-of-concept experiments in the current study performed in a murine model of Hla skin
intoxication show promise, more experimentation is required before the VLP-LND
vaccines are ready to be tested in human clinical trials.

We demonstrate that vaccination with either of two candidate VLP-based vaccines
displaying an S. aureus Hla linear neutralizing domain induces antibodies capable of
binding both the linear peptide and the native Hla toxin, suggesting the LND epitope
displayed by either VLP platform mimics the conformation of the embedded domain in the
full-length toxin. We originally hypothesized that increased maneuverability of the LND
epitope conjugated to Qβ provided by the flexible SMPH crosslinker may further enhance
molecular mimicry compared to the protein linker used for AP205-LND, inducing
antibodies with better recognition of the full-length toxin. Yet, neither platform induced
antibodies with inferior recognition of full-length Hla compared to the peptide alone,
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suggesting mimicry to the LND epitope is similar between platforms and the flexibility of
SMPH provides no advantage over the proteinaceous linker to AP205. Additionally, high
rigidity of epitopes displayed on nanoparticles such as VLPs increases the immunogenicity
compared to a flexible target273,303, therefore originally leading us to expect AP205-LND
vaccination to induce a higher titer of α-Hla antibodies than Qβ-LND. However, induced
α-Hla titers were comparable between either VLP-LND vaccine, suggesting the differences
between the two vaccines does not affect induced titer. Although quantity of induced αHla antibodies between either vaccine is similar, it is still possible the quality of antibodies
(i.e. avidity) and the longevity of antibody response may differ, and for which molecular
mimicry and rigidity304,305 can play a role. However, more experimentation is required to
determine if either VLP-LND candidate has an advantage in these qualities over the other.
Vaccination with either VLP-LND protected both male and female mice from Hlamediated pathogenesis in vivo. Reduced pathogenicity was observed as reduction in lesion
size and neutrophil influx to the site of intoxication in VLP-LND-vaccinated mice
compared to controls. Importantly, lesion size inversely correlated with Hla antibody titer,
and α-Hla antibodies were recovered from lesions of challenged mice, further suggesting
protection from Hla pathogenesis is antibody-mediated. Overall, these data demonstrate
the efficacy of the VLP-LND vaccines in reducing Hla-mediated pathogenesis.
Virus-like particles are a vaccine platform that has been increasingly recognized as
a versatile and effective technology, reflected by the increased publication records on
PubMed containing the name “virus-like particle”: from 184 publications between 19901999, to 600 publications between 2000-2009, to 1,929 publications between 2010-2019.
VLPs are highly versatile because short peptide epitopes of nearly any sequence can be
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genetically inserted in the coat protein or conjugated to the surface of assembled VLPs
while retaining capsid stability177. The multivalent, repetitive display of these short
epitopes promotes B cell receptor crosslinking, which typically results in high-titer, long
lasting humoral-mediated response177,304. The small size (20-100nm) allows for VLP
trafficking to the lymph nodes where they are taken up and presented by antigen-presenting
cells, which results in T cell activation184. VLPs carry no genetic material from the parent
virion, and therefore are non-replicative and non-pathogenic. Considering VLP vaccines
have been shown to be safe in humans (see FDA-approved Gardasil, Cervarix, and
Gardasil9178, and other phage-based VLPs in clinical trials292,293), this approach can
potentially translate into human studies more readily than other novel approaches. Here we
report the first VLP-based vaccine targeting Hla induces a high titer of α-Hla antibodies in
mice, but determining the longevity of antibody response requires further experimentation.
No difference between VLP platforms was observed in α-Hla titers induced nor protection
from Hla-mediated pathogenesis, but cost benefit should be weighed when selecting a
single VLP-LND to bring to an upscaled production phase177,294.
In this moment of antibiotic-resistant bacteria posing a great threat to human health,
novel and effective treatment options are direly needed. These two candidate VLP-based
vaccines, AP205-LND and Qβ-LND, both demonstrated the ability to induce an antibody
response that neutralizes the key S. aureus cytotoxin, Hla, and reduce severity of Hlamediated pathogenesis in a model of murine skin intoxication. Although more
experimentation is needed, we anticipate these VLP-LND vaccines being an effective
single component of a multi-component S. aureus vaccine, which may reduce the risk of
severe infection in at-risk populations.
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Conclusions
Novel treatment and prevention strategies are urgently needed to combat infections caused
by antibiotic resistant S. aureus. Here, we describe two candidate VLP-based vaccines,
AP205-LND and Qβ-LND, with demonstrated efficacy in the prevention of Hla-mediated
pathogenesis in a murine skin intoxication model. Although further studies are required,
the efficacy of these vaccines and the clinical utility of VLP-based vaccines in general,
suggests that they could contribute to a multi-component S. aureus vaccine.

Materials and Methods
Ethics Statement
Animal experiments described in this study were approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of New Mexico Health Sciences Center
(Animal Welfare Assurance number D16-00228) and conducted in strict accordance with
recommendations in the Guide for Care and Use of Laboratory Animals279 the Animal
Welfare Act, and U.S. federal law.

VLP cloning, expression, and purification
The pAPKP plasmid encoding the AP205 coat protein and C-terminal linker
(GTAGGGSGT) was used for generation of AP205-LND. The pAPKP plasmid was
derived from pBAD-thio-TOPO-AP205, provided by Kaspars Tars of the Latvian
Biomedical Research and Study Centre, Riga. It is based on pBAD-thio-TOPO
(ThermoFisher, Grand Island, NY) and expresses AP205 coat protein from the E. coli
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arabinose promoter. We constructed pAPKP by modifying pBAD-thio-TOPO-AP205 to
encode a linker peptide at the coat protein C-terminus similar to that described by Tissot et
al in 2010294. Briefly, the E. coli optimized Hla-LND sequence was synthesized as a minigene in IDT’s pSMART plasmid (Integrated DNA Technologies, Coralville, IA). We fused
foreign peptides to coat protein through the linker by insertion of their coding sequences
between the KpnI and PstI sites of pAPKP and the LND-insert. Complete plasmid
sequences are available upon request. The pAPKP-Hla-LND was transformed into E. coli
5αF’Iq for transcription followed by transformation into E.coli BL21*DE3 for expression.

Wild type Qβ was expressed from plasmid pETQCT and purified from Escherichia coli
(E. coli) as previously described182,306. The synthetic Hla-LND peptide (Hla 119-131;
GFNGNVTGDDTGKIGGLIGAN), including an N-terminal cysteine residue followed by
a three-glycine-spacer sequence (CGGG-LND), was synthesized by GenScript
(Piscataway, NJ) then conjugated to Qβ’s surface-exposed lysine residues using the
bifunctional crosslinker succinimidyl 6-[(beta-maleimidopropionamido) hexanoate]
(SMPH; 22363; Thermo Scientific, Waltham, MA)307.

Wild type AP205 and AP205-LND were expressed and purified from BL21*DE3.
Overnight cultures on 50 ug/mL kanamycin (Sigma-Aldrich, Burlington, MA) were grown
in 2xYT (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl; BD Biosciences, Franklin
Lakes, NJ). Expression strains of both AP205 and AP205-LND were grown overnight on
media with kanamycin and used to inoculate a 50 to 500 mL culture with shaking. When
OD600 nm surpassed 0.6, the culture was induced with 0.2 % w/v arabinose and incubated
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for an additional 3 h. The cells were pelleted by centrifugation and VLPs were purified via
FPLC. Purity was confirmed as previously described296.

Mouse immunizations
Four-week-old male and female BALB/c mice (Jackson Laboratories, Bar Harbor, ME)
were immunized by injection of 50-60 μL vaccine mixture in the caudal thigh muscle.
Vaccines contained 10 μg VLP suspended in sterile PBS, mixed 1:1 in Incomplete Freund’s
Adjuvant (Invivogen, San Diego, CA), or mock vaccinated with PBS alone. Four weeks
later, mice were given an identical vaccination (boost). Serum for ELISAs was collected
by retro-orbital bleed or at the time of euthanasia by cardiac puncture. Challenge
experiments were performed eight weeks after boosting.

Hla and LND Peptide ELISA
Vaccine-elicited murine serum antibody binding to Hla was determined by ELISA. ELISA
plates were prepared by coating Ultra Cruz ELISA High-Binding plates (Santa Cruz
Biotechnology, Santa Cruz, CA) with 125 ng per well of rHla in 50 μL carbonatebicarbonate buffer (pH 9.5) and incubated overnight (approximately 16-18 h) with shaking
at 4°C. After incubation, liquid was removed and wells were blocked with PBS containing
1% casein (Thermo Scientific) + 0.05% Tween-20, and then incubated for 2 h at 22°C with
shaking. Sera from vaccinated mice were serially diluted either 2-fold or 4-fold for control
samples, added onto the Hla-coated wells for antibody binding to Hla, and incubated at
22°C for 1 h with shaking. After serum antibody (Ab) binding, excess liquid was removed,
and plates were washed three times using PBS containing 0.05% Tween-20 (PBS-T).
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Murine Ab bound to Hla was detected using polyclonal goat anti-mouse IgG secondary
antibody linked to HRP (32230, Invitrogen) and assays were developed using 1-StepTM
Ultra TMP-ELISA according to manufacturer’s directions. Hla titer was calculated as the
reciprocal of the dilution value of the furthest diluted well with absorbance greater than
two times the average of background (naïve sera). The lower limit of detection (LLOD)
was a titer of 100. For detection of anti-Hla IgG Ab in Hla lesions, lesion homogenates
collected from Hla-challenged mice, as reported below, were used in place of serum in the
Hla ELISA.

For the LND peptide ELISA, streptavidin was coated to Immulon II ELISA plates (Thermo
Scientific) at 500 ng per well in pH 7.4 PBS overnight at 4°C. Unbound streptavidin was
removed by washing with PBS, then SMPH (22363; Thermo Scientific) was added at 1 µg
per well and incubated for 1 h at room temperature with shaking. After washing with PBS,
1 µg of synthetic CGGG-LND peptide (GenScript) was added to each well and incubated
for 1 h at room temperature with shaking. Unconjugated peptide was removed by washing
with PBS, plates were blocked with PBS + 0.5% non-fat dry milk, and the ELISA was
conducted as described above.

Toxin Neutralization Assay
Vaccine-elicited Hla-neutralizing Ab were detected in vitro by toxin neutralization assay,
similar to that described by Oscherwitz and Cease143 using the Jurkat human T cell line
(TIB-152, ATCC, Manassas, VA). Jurkat cells were grown in RPMI 1640 (Life
Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum and 50 μM
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beta-mercaptoethanol (BME) (complete medium) in a humidified 5% CO2 incubator at
37°C. 50 μL of vaccinated mouse sera diluted 1:12 in complete medium was plated in
triplicate in a 96-well polystyrene plate (Corning Incorporated, Corning, NY) and
incubated with 50 μL rHla at 0.8 μg/μL for 30 min at 37°C. Approximately 100,000 Jurkat
cells in 100 μL complete medium were combined with the sera-rHla mixture and incubated
at 37°C. After 2 h incubation, 100 μL of 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2Htetrazolium-5-carboxanilide (XTT; Sigma-Aldrich, St. Louis, MO) at 0.3 mg/mL and
phenazine methosulfate (PMS; TCI America, Portland, OR) at 0.015 mg/mL diluted in
complete medium was added to the wells. After 18 h incubation, absorbance at 450 nm was
measured using a SpectraMax 340 microplate reader (Molecular Devices, San Jose, CA).
As a positive control, 8B7 Hla-neutralizing antibody (0210-001, IBT, Rockville, MD) was
added to naïve mouse sera.

Mouse skin intoxication model
The murine model for Hla-mediated lesion formation was essentially performed as
previously described213. Briefly, the right flank of vaccinated male or female BALB/c mice
was cleared of hair by shaving and depilation two days prior to intoxication. Because
female mice are more resistant to Hla compared to males308, in an effort to achieve similar
size lesions between the sexes, male mice were challenged with 1.25 µg of Hla while
females were challenged with 2 µg,. On the day of intoxication, rHla was diluted in 50 μL
saline (Braun, Irvine, CA). Mice were anesthetized by isoflurane inhalation and injected
subcutaneously with rHla in saline. Mice were weighed on the day of injection and daily
thereafter until sacrifice. The site of intoxication was photographed daily and lesion size
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was determined by analysis with ImageJ282. Three days after intoxication, mice were
sacrificed by CO2 asphyxiation and a 225-mm2 skin section containing the lesion was
excised and stored in Hank’s Balanced Salt Solution (HBSS; Life Technologies) containing
10 mM HEPES. Lesions were homogenized by mechanical disruption and the clarified
fraction was stored at -80°C with 1x HaltTM protease inhibitor (Thermo Scientific) for
further analysis.

Histology
Histological evaluation was performed as previously reported308, with skin samples
collected on day 3 post-Hla intoxication. A 225-mm2 piece of skin containing the site of
Hla injection was flattened on cardboard, fixed for 24 hours in neutral buffered formalin,
and then stored in 70% ethanol. Fixed skin was bisected through the center of the injection
site and processed for embedding in paraffin, sectioned at 5 μm thickness, and stained with
hematoxylin and eosin (H&E). Slides of H&E stained skin sections were scanned by an
Aperio CS2 scanner (Leica Biosystems, Buffalo Grove, IL).

Statistical analyses
Statistical analyses were performed using GraphPad Prism 8.4.2. Differences were
considered statistically significant at p<0.05.
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CHAPTER 4: Conclusions and Future Considerations

Staphylococcus aureus is the cause of many types of infections plaguing humans21, and the
prevalence of antibiotic-resistant strains, estimated over 50% for MRSA strains30,31, led to
its classification as a “serious health threat” by the CDC53. There has yet to be a S. aureus
vaccine to show success in phase III of clinical trials, therefore effective treatments are
urgently needed. As covered previously and in greater detail, possible reasons for the
failure of S. aureus vaccines attempted thus far could be due to the exclusive pursuit of an
antibody response promoting opsophagocytic uptake of S. aureus, or that too few virulence
factors were the targets of vaccination to demonstrate effective protection (see Table 1.3).
However, inducing a NAb response against toxins and other virulence factors that promote
infection holds promise on the basis that preventing toxin-mediated lysis of innate immune
protective cells and phagocytes should allow for enhanced S. aureus clearance by the
host155. Additionally, disruption of a multitude of virulence factors ranging in function
from cell lysis, tissue damage, promotion of inflammation, mediating invasion to distal
sites, and immune evasion should limit the ability for S. aureus to cause disease. Therefore,
treatments incorporating these approaches hold promise in effectively limiting S. aureus
infection severity. Thus, alternative or entirely novel approaches, such as VLP-based
vaccines, may help address the S. aureus crisis.
The work summarized here in Figure 4.1 significantly advances the current antivirulence tools against S. aureus as follows. First, in Chapter 2 we describe the
development of PP7-AIP1S, a novel VLP-based vaccine targeting AIP1, the quorum
sensing pheromone utilized by agr-I S. aureus strains. We found that vaccination with PP783

AIP1S induced antibodies capable of binding to AIP1 in its native form. PP7-AIP1S
vaccination protected mice during SSTI challenge of an agr-I S. aureus strain and limited
the inflammatory response during challenge. We also observed that agr-I signaling was
inhibited in vivo, with the additional reduction in abscess levels of Hla, which is regulated
by agr. This is the first reported approach to disrupt agr-I signaling by active vaccination
(findings summarized in Figure 4.1A). In Chapter 3, we describe the development of
AP205-LND and Qβ-LND, two novel VLP-based vaccines targeting a linear neutralizing
domain on Hla. We found vaccination of mice with VLP-LNDs induced α-Hla NAbs that
protected target cells from Hla-mediated lysis. Furthermore, VLP-LND vaccination
protected mice from Hla subcutaneous challenge, which resulted in a reduction in lesion
size and the absence of a neutrophilic barrier to the site of intoxication. These vaccines are
the first VLP-based vaccines developed targeting S. aureus toxins and are also the first to
target the Hla 119-139 domain by active vaccination (findings summarized in Figure
4.1B).
The discussion below will address the limitations to the approaches described and
the gaps in knowledge that still exist, additionally providing a discussion for how concerns
might be addressed or expanded. Specifically, this includes future considerations for
targeting agr by PP7-AIP1S and targeting Hla by VLP-LND vaccination, approaches to
enhance vaccine efficacy, and defining the potential clinical utility of these vaccines.
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Figure 4.1 - VLP-Based vaccines induce neutralizing antibodies against agr and Hla.
(A) Inhibition of agr by induced antibody response from PP7-AIP1S vaccination. (B)
Inhibition of Hla-mediated cell lysis and tissue damage from VLP-LND vaccination. Hla
figures produced using PyMOL.
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Future considerations for PP7-AIP1S vaccine and targeting agr
Although the development of the PP7-AIP1S vaccine targeting agr-I signaling advances
the current knowledge of both S. aureus quorum sensing inhibitors and of S. aureus
vaccines in general, there are still gaps in knowledge that remain surrounding this method
of treatment. These questions include but are not limited to: (i) in what ways is targeting
agr-I limited in scope, (ii) will targeting other virulence pathways or factors in addition to
agr promote S. aureus clearance, and (iii) does inhibiting agr signaling promote biofilm
formation in vivo?
We determined vaccination with PP7-AIP1S inhibits agr-I signaling in vivo and
limits pathogenicity during SSTI challenge with an agr-I S. aureus strain. Strains carrying
the agr-I allele are most commonly associated with invasive SSTI, yet three other agr
alleles exist: agr-II, -III, and -IV, and isolates of each type cause disease83. Therefore, a
vaccine approach targeting a single agr allele is limited to only protecting against a fraction
of all S. aureus SSTIs. To address this concern, we plan on developing vaccines targeting
the remaining AIP2, AIP3, and AIP4 quorum sensing molecules. Considering the
successful induction of NAbs against AIP1 by vaccination with PP7-AIP1S, where the
AIP1S sequence was conformationally restricted in the AB loop of PP7, a logical approach
to designing AIP2-4 vaccines while maintaining molecular mimicry is to clone AIP2S,
AIP3S, and AIP4S sequences into the PP7 AB loop (Figure 4.2). However, it is not
guaranteed the PP7 platform will work equally well for all AIP sequences. A single-chain
dimer modification on the coat protein of MS2 VLP also allows short peptide insertion in
the AB loop without a loss of stability197, providing another potentially suitable option. If
successful in developing each VLP-AIP vaccine, a universal quadrivalent vaccine
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Figure 4.2 - Pending questions for VLP-AIP vaccines inhibiting AIP1-4. Will VLP
platforms displaying modified AIP2, AIP3, and AIP4 effectively induce NAbs capable of
agr-II, -III, and -IV inhibition, respectively? Can PP7-AIP1S vaccination provide crossinhibition of AIP4?
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incorporating each VLP-AIP and therefore inhibiting agr-I, -II, -III, and -IV can be
plausibly developed. Also holding promise is the potential for PP7-AIP1S vaccination to
induce cross-inhibitory antibodies against AIP4, as demonstrated in Figure 4.2. The
primary amino acid sequence between AIP1 and AIP4 differ by a single amino acid, and
we have preliminary results showing PP7-AIP1S-induced antibodies bind AIP4 in addition
to AIP1 in a competition ELISA (unpublished). Successful inhibition of agr-IV signaling
in addition to the previously demonstrated agr-I signaling by PP7-AIP1S vaccination
would further extend the clinical utility of this vaccine, although this requires further
investigation. However, another important consideration is the potential for a universal
agr-I-IV vaccine selecting for S. aureus strains of a single agr allele if the antibody
response to one of the four AIP targets is not as effective as the others. This could be the
result of a VLP-AIP exhibiting worse molecular mimicry to native AIP. In that case, either
modification to the AIP sequence in the vaccine by either lengthening or shortening should
occur to obtain potentially better mimicry, or individual VLP dose or boosting should be
implemented to ensure equivalent AIP-neutralizing titer is induced to all four AIP targets
by the universal quadrivalent AIP1-4 vaccine.
Although agr is one of the best-studied virulence regulatory systems, and much of
S. aureus virulence is regulated by it, agr is not the only virulence factor regulatory system.
The SaeRS TCS differentially regulates 20 virulence factors including both exotoxins,
adhesins, and immune evasion factors64, and has also been found to play a role in dictating
infection severity62,77,105. Both agr and sae deletion mutants of USA300 parent strains have
significantly attenuated virulence77. The SarA system also regulates S. aureus virulence
independent of agr109, yet SarA activation can also enhance agr activity309,310. An approach
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aimed at inhibition of SaeRS or SarA activity paired with agr inhibition via PP7-AIP1S
vaccination may hold promise in enhancing inhibition of virulence. Such inhibitors have
not yet been reported, but these would likely be small-molecule inhibitors considering
SaeRS signaling occurs intracellularly and the SarA system is entirely cytosolic64.
Importantly, Hla is regulated not only by agr, but by sae and sarA as well99,311. Vaccination
with PP7-AIP1S significantly reduced Hla expression, but still showed approximately 20%
transcriptional activity (Figure 2.4 C). Therefore, further protection from Hla-mediated
pathogenesis should be explored with co-vaccination with VLP-LND vaccines, to induce
an α-Hla response, in addition to targeting agr by PP7-AIP1S vaccination.
An important consideration is the concern over the potential for agr inhibition
enhancing the production of biofilm. Inhibited agr has an increased display of
MSCRAMMs, which promote adhesion65. Such virulence factors also play a role in the
adherence step of biofilm development17. Therefore, there is some caution in using agr
inhibitors against S. aureus because of the presumption of biofilm promotion. However,
agr inhibition enhancing biofilm size is highly strain-dependent258. We also postulate that
due to suppression of pore-forming toxin expression preserving immune cells during agr
inhibition, enhanced bacterial clearance will occur. Further supporting this is agr-negative
isolates are significantly less virulent than agr-positive in most types of infection. Strains
with dysfunctional agr are commonly associated with bacteremia in humans264,312, but we
postulate that without agr-regulated virulence factors mediating invasion, such as
proteases, lipases, and toxins, the risk should be relatively low for an agr+ strain with
inhibited agr signaling disseminating from an SSTI and causing bacteremia before being
cleared by a viable innate immune response. One future consideration we have made is to
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use the increased MSCRAMM expression as a potential advantage. We anticipate
increased MSCRAMM expression on the surface of S. aureus might be possible targets for
an antibody-mediated opsonophagocytic response. Particularly, recent studies identified
FnBPA conformational epitopes and a short linear epitope in the FnBPA N2N3 subdomain,
which induce FnBPA-binding antibodies upon murine vaccination and promote survival
during S. aureus i.p. challenge313,314. Identification of these peptides opens the door for the
development of a VLP-based FnBPA vaccine using these epitopes, by cloning or
conjugation. Targeting overexpressed FnBPA paired with antibody-mediated agrinhibition from PP7-AIP1S vaccination is a potentially promising option requiring
investigation (Figure 4.3). If S. aureus clearance is promoted by this method, vaccination
with other surface-displayed virulence factors negatively regulated by agr can be pursued
as well. As stated above, previous S. aureus vaccines that exclusively induced opsonizing
antibodies surface-displayed targets ultimately failed in human trials. However, the
potential for the combined neutralizing and opsonic antibody response has not yet failed,
but instead is the basis for several vaccines in development (see Table 1.3). Furthermore,
vaccine-induced opsonization has not yet been tried in the context of agr inhibition, and
overexpression of a targeted surface protein may help overcome SpA and Sbi antibody
capture.
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Figure 4.3 - Considerations for combined AIP and FnBPA vaccine. (1) PP7-AIP1S
vaccine induces NAbs against AIP1. (2) Inhibition of agr leads to increase in MSCRAMM
transcription. (3) Increase in transcription increases surface displayed FnBP. (4) Can
surface-displayed FnBP be targeted by vaccine-induced antibodies? (5) Will vaccination
against FnBPA further promote clearance of S. aureus?
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Future considerations for VLP-LND vaccines and targeting Hla
The development of AP205-LND and Qβ-LND significantly advances the field of vaccines
targeting S. aureus toxins. These are the first VLP-based vaccines to target Hla and the first
vaccines to target the Hla 119-139 domain by active vaccination. However, several
important questions remain, including: (i) to what extent is Hla function inhibited by VLPLND-induced antibodies, (ii) what advantages do these vaccines carry over other α-Hla
vaccines, and (iii) in what ways can this platform be used to further enhance vaccine
efficacy?
In Chapter 3, we demonstrated both AP205-LND and Qβ-LND protected male and
female BALB/c mice from Hla-mediated pathogenesis in a subcutaneous Hla challenge,
however it is yet to be determined if these vaccines protect from S. aureus infection. Active
vaccines and mAbs against Hla have been used to show reduced pathogenicity and bacterial
burden in SSTI128,284, PNA118,283, sepsis285,286, peritonitis284, and others287–290. Considering
the important role Hla plays in S. aureus pathogenicity in both SSTI and PNA, we expect
VLP-LND vaccination will also provide protection. We observed a reduction in lesion size
and neutrophil influx to the site of intoxication, yet further investigation must be performed
to determine if VLP-LND vaccination also protects from sub-lytic effects such as the
expression of pro-inflammatory cytokines IL-1β and IL-18, which are induced by Hlamediated activation of the NLRP3 inflammasome115. Hla also disrupts cell junctions by
activation of ADAM10 followed by E-cadherin cleavage114, therefore it must also be tested
if VLP-LND vaccination limits junction disruption and furthermore prevents S. aureus
dissemination. Demonstrating these additional levels of protection would reveal further
value in the utility of the VLP-LND vaccines.
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Although the vaccines described here are the first VLP-based Hla vaccines, they
are not the first vaccines to target Hla by active vaccination. A key advantage provided by
epitope display by VLPs is a long-lasting high titer focused antibody response185. Whole
pathogen or pathogen-derived subunit vaccines have successfully been developed and
utilized to protect against a large number of pathogens with great success, including
smallpox and polio, but considering the clinical failures of S. aureus vaccines, a more
sophisticated approach such as an epitope-focused vaccine may prove more efficacious.
Since epitope-focused vaccines can effectively induce focused neutralizing antibody titers
directed at neutralizing epitopes187, VLP-LND vaccine responses should be tested in a
concomitant study with other Hla vaccines such as the HlaH35L or AT62 vaccines to
determine if the VLP platform used here provides an advantage over other Hla vaccines in
development. Another important consideration is the longevity, or durability, of antibody
response. Multivalent antigens imprint an extended lifespan on long-lasting plasma cells,
often leading to a durable, high-titer antibody response to multivalent vaccines304,305.
Therefore, the longevity of α-Hla antibodies induced by VLP-LND vaccination compared
to monovalent Hla vaccines should be investigated, which may demonstrate greater clinical
utility lies with the vaccines described here.
Hla is a desirable target for neutralization considering its nearly ubiquitous
expression and important role in S. aureus diseases283. Although their expression is not as
ubiquitous as Hla, there are other pore-forming toxins used by S. aureus that are important
in infection, including delta-toxin and the bicomponent leukotoxins: Panton-Valentine
leucocidin (PVL), LukDE, LukAB, and gamma-toxin315,316. The S. aureus leukotoxins are
structurally conserved, and a single monoclonal antibody against a conserved
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conformational epitope has been developed capable of neutralizing all four toxins in
addition to Hla317. A similar approach may be taken to display a conserved leukotoxin
epitope by VLP to induce active immunity to these toxins and may further enhance
protection when paired with VLP-LND vaccination.
When considering what can be incorporated to enhance VLP-LND efficacy,
immune function required for clearance of S. aureus can be highlighted. Recently more
focus has been put on the important role Th17-mediated immunity plays in S. aureus
infection, which is now believed to be a requirement for S. aureus clearance46. The lack of
Th17 immunity may have contributed to the failure of V710, as a post-trial analysis found
9 of 10 patients with non-existent preoperative IL-17 levels and postoperative S. aureus
infection died148. Th17-activating vaccines against S. aureus are relatively unexplored but
have shown some early success (see NovaDigm Therapeutic’s NDV3163). Mucosal
delivery may direct immunity to a Th17 response318. Also able to direct a Th17 response
are adjuvants, such as an oil-in-water nanoemulsion319 or cyclic dinucleotides (CDNs)320,
which adjuvanted a ClfA vaccine and was shown to stimulate innate immune cells to better
clear S. aureus321. Either mucosal delivery or adjuvant can be tested with the VLP-LND
vaccines in attempt to trigger the induction of an increased Th17 response that may provide
enhanced protection via S. aureus clearance (Figure 4.4). However, whether this approach
enhances clearance and does not cause further non-specific inflammation or host tissue
damage, and does not sacrifice α-Hla NAb titer, requires investigation.
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Figure 4.4 - Considerations for inducing Th17 immunity with VLP-LND vaccination.
(1) Hla causes lysis of neutrophils, which typically perform S. aureus clearance during
infection. (2) Th17 adjuvant activates Th17-mediated immunity, which recruits neutrophil
and clears S. aureus. (3) Vaccination with VLP-LNDs induces α-Hla-LND NAbs, which
inhibits Hla-mediated lysis of innate immune cells. Does immune cell preservation result
in S. aureus clearance? (4) Does VLP-LND vaccination combined with Th17 adjuvant
enhance innate immune response? Does enhances immune response have enhanced S.
aureus clearance?
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Clinical utility and future considerations for S. aureus VLP-based vaccines
Although the preclinical results for both PP7-AIP1S and VLP-LND vaccines are
promising, there are remaining questions pertaining to clinical utility. Particularly, these
questions include: (i) who might benefit the most from these VLP-based S. aureus
vaccines, (ii) will S. aureus develop resistance to these vaccines, and (iii) what beneficial
long-lasting effects might these vaccines provide?
We anticipate those at high risk of S. aureus infection would benefit from these
vaccines. These populations include elderly, prisoners, athletes, active duty military, and
those undergoing invasive surgery. Those with genetic defects predisposing to high risk of
infection, such as those with Job’s Syndrome or CGD may also find value in these
vaccines35–39. The agr pathway is active at both 3 h and 72 h post-infection76, therefore
vaccination or prophylactic inhibition should provide the most benefit by limiting agr
activation and virulence factor production upfront. Considering Hla is under agr control,
and that tissue damage begins early in infection, VLP-LND vaccines may show best
efficacy against most types of S. aureus infection when used prophylactically as well. Hla
and agr are known to play a large role in SSTI and PNA; therefore, both vaccines are
anticipated to limit pathogenesis for both types of infection.
A highly important consideration is the potential for resistance to develop against
these vaccines. Kennedy et al.322 claims vaccines are less vulnerable to pathogen evolution
than antimicrobial drugs because of two primary reasons: (i) the prophylactic timing of
vaccines, which limits pathogen replication before a large population provides
opportunities for mutation to arise, and (ii) providing multiple binding sites on a single
epitope, essentially serving as a form of combination drug therapy that might require
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multiple simultaneous mutations to occur in order to escape. Both vaccines are planned to
be used prophylactically, which should limit tissue damage and immune cell lysis upfront
to provide enhanced clearance of S. aureus, thereby preventing a large population of S.
aureus and limiting the risk of developing mutations in either AIP or Hla targets. With
regard to the second point, it is yet to be determined where induced antibodies are binding
on AIP or Hla, and it is unknown if every potential binding sites on these targets are equally
neutralizing. Importantly, resistance to PP7-AIP1S will be particularly difficult because
AgrB and AgrC are both highly intolerant to sequence modification of AIP70, meaning
functional agr after AIP (AgrD) mutation also requires a gain-of-function mutation in both
AgrB and AgrC, which is highly unlikely. Resistance developing against the VLP-LND
vaccines may be more possible, yet still unlikely given the above circumstances to
resistance developed to vaccines. Another important consideration is that both vaccines
should have low selection pressure because neither is directly antibacterial. In fact, the term
“accessory” in agr stems from the fact this pathway is not necessary for normal growth.
Therefore, we expect the overall potential for resistance against PP7-AIP1S and VLPLNDs is extremely low, if existent at all, yet resistance studies still must be performed to
confirm this.
An additional consideration pertaining to the clinical utility of both types of VLPbased S. aureus vaccine pertains to longevity, or durability, of antibody response. The
durability of antibody circulation will dictate how often boosting should be implemented
in humans, if necessary. Vaccination may protect humans to primary S. aureus infection,
but will titers remain high after the initial insult and protect during secondary infection?
This is an important question considering the high frequency of S. aureus reinfections123.
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Furthermore, will vaccination prime memory B cells to antigens to better respond to future
S. aureus infections? Such a response could address the issue that infection likely does not
lead to protective immunity whereas this vaccine would provide such protection. The
answer to each question is currently unknown and requires future investigation.

Conclusion
When developing a vaccine to a pathogen against which many others have resulted in
clinical failure, the most important question that needs addressing is: “In what ways does
this vaccine overcome the failures of vaccines of the past?”. Although the cause for past
failures has not been definitively determined, vaccines that neutralize virulence hold
promise. PP7-AIP1S and the VLP-LND vaccines significantly advance the field of S.
aureus vaccine development by providing two novel, efficacious, VLP-based vaccines
proven to neutralize virulence in animal models. These findings may open the door for the
use of VLPs to target a greater number of S. aureus virulence factors in pursuit of a highly
effective universal S. aureus vaccine. Yet much more investigation is still required. Since
it is not possible to predict the agr type of S. aureus during infection, a vaccine capable of
inhibiting agr-I-IV must be developed. Additionally, incorporating elements such as an
opsonic response to upregulated surface proteins during agr inhibition or an enhanced
Th17 immune response may further promote vaccine efficacy. Although more is required
before these vaccines are ready for the clinic, novel approaches such as these may help
answer the call to the current health crisis imposed by S. aureus.
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APPENDIX A: Abbreviations
Ab - antibody
ABSSSI – acute bacterial skin and soft structure infection
ADAM10 – A disintegrin and metalloproteinase domain-containing protein 10
agr-I-IV – accessory gene regulator type I-IV
AIP1-4 – autoinducing peptide 1-4
Als3p – agglutinin like sequence 3 protein
BME – beta-mercaptoethanol
BSI – blood stream infection
C. albicans – Candida albicans
CA-MRSA – community-acquired MRSA
CDC – Centers for Disease Control and Prevention
CDN - cyclic dinucleotide
CFU – colony-forming unit
CGD – Chronic Granulomatous Disease
ClfA, ClfB – clumping factor A, clumping factor B
Coa – coagulase
CP5, CP8 – capsular polysaccharide 5, capsular polysaccharide 8
Csa1A – conserved staphylococcal antigen 1A
DMSO – dimethyl sulfoxide
DT – diphtheria toxoid
EsxA, EsxB – secretion system protein A, secretion system protein B
ELISA – enzyme-linked immunosorbent assay
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FBS – fetal bovine serum
FDA – Food and Drug Administration
FhuD2 – ferric hydroxamate receptor D2
FnBPA, FnBPB - fibronectin-binding protein A, fibronectin-binding protein B
FPLC – fast protein liquid chromatography
Fr – ferret; Mustela putorius furo
FU - Floxuridine
GBAP – gelatinase biosynthesis-activating pheromone
GI – gastrointestinal
GSK - GlaxoSmithKline
GST – glutathione S-transferase
HA-MRSA – hospital-acquired MRSA
HBSS – Hank’s buffered saline solution
HCV – Hepatitis C Virus
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
H&E – hematoxylin and eosin stain
Hla – alpha-hemolysin (Alpha-toxin)
HPV – Human Papilloma Virus
HRP – horseradish peroxidase
IACUC – Institutional Animal Care and Use Committee
IAUPS – Islamic Azad University, Pharmaceutical Sciences Branch
IBT – Integrated BioTherapeutics
i.d. - intradermal
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IgG – immunoglobulin G
i.m. - intramuscular
i.p. - intraperitoneal
IPTG – isopropyl-β-D-1-thiogalactopyranoside
IsdA, IsdB – iron-regulated surface determinant A, iron-regulated surface determinant B
LND – linear neutralizing domain
LukS-PV – Panton-Valentine leucocidin component S
LZD – linezolid
mAb – monoclonal antibody
MAP – multiple antigenic peptide
MGE – mobile genetic element
MntC – manganese transport protein C
MOA – mechanism of action
mRNA – messenger ribonucleic acid
MRSA – methicillin-resistant Staphylococcus aureus
Ms – mouse; Mus musculus
MSCRAMMs - microbial surface components recognizing adhesive matrix molecules
MSSA – methicillin-sensitive Staphylococcus aureus
MWCO – molecular weight cutoff
NAb – neutralizing antibody
NIAID – National Institute of Allergy and Infectious Diseases
NIH – National Institutes of Health
NLRP3 – NOD-like receptor family, pyrin domain containing 3
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NSFC – National Natural Science Foundation of China
OD – optical density
OHM – ω-hydroxyemodin, also omega-hydroxyemodin
PAGE – polyacrylamide gel electrophoresis
PBS – phosphate buffered saline
PBP2a – penicillin-binding protein 2a
PCR – polymerase chain reaction
PMS – phenazine methosulfate
PNA – pneumonia
PSM – phenol soluble modulin
PVL - Panton-Valentine leucocidin
qPCR – quantitative polymerase chain reaction
QS – quorum sensing
Rb – rabbit; Oryctolagus cuniculus
RIP – RNAIII-inhibiting peptide
RNA – ribonucleic acid
ROS – reactive oxygen species
Rot – repressor of toxins
RPMI – Roswell Park Memorial Institute medium
RSV – Respiratory Syncytial Virus
RT – room temperature
RT-PCR – reverse transcriptase polymerase chain reaction
S. aureus – Staphylococcus aureus
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S. caprae – Staphylococcus caprae
S. pneumoniae – Streptococcus pneumoniae
S. simulans – Staphylococcus simulans
Sae – S. aureus exoprotein expression
SdrD, SdrE – serine-aspartate repeat protein D, serine-aspartate repeat protein E
SDS – sodium dodecyl sulfate
SEA, SEB – staphylococcal enterotoxin A, staphylococcal enterotoxin B
s.e.m. – standard error of the mean
SpA – surface protein A
SSTI – skin and soft tissue infection
STAT3 – signal transducer and activator of transcription 3
STRIVE – STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy
TBST – tris-buffered saline (plus tween-20)
TCS – two-component system
Tdap – Tetanus, Diphtheria, Pertussis
TSB – Trypticase soy broth
TT – tetanus toxoid
TSST-1 – toxic shock syndrome toxin-1
USUHS – Uniformed Services University of the Health Sciences
VAN – vancomycin
VISA – vancomycin-intermediate Staphylococcus aureus
VLP – virus-like particle
VRI – Vaccine Research Institute
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VRSA – vancomycin-resistant Staphylococcus aureus
WT – Wild type
WTA – wall teichoic acid
XLA – X-Linked Agammaglobulinemia
XTT – (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide)
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